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Abstract 
Lipotoxicity is implicated as a mechanism for pancreatic P-cell dysfunction in 
obesity-induced type 2 diabetes (T2D). In vitro, peroxisome proliferator-activated 
receptor alpha (PPARa) protects against lipotoxic (3-cell dysfunction preserving insulin 
secretion. Utilizing an adeno-associated virus (dsAAV8), we induced overexpression of 
PPARa specifically in pancreatic p-cells of adult, C57B16 mice that were fed a high-fat 
diet for 20 weeks to induce obesity. We show that overexpression of PPARa in 
pancreatic P-cells, in vivo, protects P-cell function in obesity, improving glucose 
tolerance by preserving insulin secretion compared to obese controls. No change in islet 
morphology or P-cell mass was observed. Despite metabolic improvements observed in 
diet-induced obese mice, overexpression of PPARa in pancreatic P-cells of a genetic 
model of severe obesity (db/db) did not improve carbohydrate metabolism. We have 
developed the first in vivo model of p-cell specific PPARa overexpression to elucidate 
the mechanisms involved in P-cell lipotoxicity in obesity-induced T2D. 
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Figure 1.3 Obesity as a conduit to insulin resistance and p-cell dysfunction - modified 
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altered adipokine profiles, and lipid accumulation in non-adipose tissues, propagating the 
pathogenesis of insulin resistance and P-cell dysfunction. When the cells and peripheral 
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resistant state, the islets make more insulin (hyperinsulinemia) to compensate to maintain 
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Abbreviations: TNF-a - Tumor Necrosis Factor alpha; IL-6 - Interleukin 6; PAI-1 -
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genomes/mouse) or saline (284^1/mouse). Body weights (weekly), 4hr fasted blood 
glucose readings (biweekly), oral glucose tolerance (end point), and insulin tolerance 
(end point) were assessed. Abbreviations: dsAAV8 - double stranded adeno-associated 
virus serotype 8; RIP - rat insulin promotor; eGFP - enhanced green fluorescent protein. 
Figure 2.2 Immunohistochemical analysis to detect eGFP overexpression in pancreatic P-
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cells (A) and not a-cells (B) of the pancreas of C57B16 mice. (C) Percentage of eGFP 
positive immunoreactive area in total islet area. Abbreviations: dsAAV8 - double 
stranded adeno-associated virus serotype 8; RIP - rat insulin promotor; eGFP - enhanced 
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Figure 2.3 Western blot analysis of dsAAV8-RIP-eGFP expression in the hypothalamus. 
Overexpressing dsAAV8-RIP-eGFP in pancreatic P-cells does not cross the BBB 
showing no expression in the hypothalamus. 30|ig of protein per sample was loaded and 
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double stranded adeno-associated virus serotype 8; RIP - rat insulin promotor; eGFP -
enhanced green fluorescent protein; NT - non-transfected MIN6 cells; (-) negative 
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Abbreviations: dsAAV8 - double stranded adeno-associated virus serotype 8; RIP - rat 
insulin promotor; eGFP - enhanced green fluorescent protein; 1° - primary; CNTRL -
control. Images taken at 20x magnification. Scale bar 50(am. 
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dsAAV8-RIP-eGFP (p-eGFP-Control) or saline (284|il/mouse) by ip injection. 
Overexpression of eGFP in pancreatic P-cells resulted in no change in body weight (A), 
4hr FBG (B), glucose tolerance (C, 2g D-glucose/kg), or insulin sensitivity (D, 0.75U 
insulin/kg) compared to saline-treated mice on regular chow diet. Abbreviations: 
dsAAV8 - double stranded adeno-associated virus serotype 8; RIP - rat insulin promotor; 
eGFP - enhanced green fluorescent protein; FBG - fasted blood glucose. Saline-treated 
n=7, P-eGFP-Control n=7. Mean values +/- standard error of the mean are shown. 
Statistical significace was determined by 2-way ANOVA (over time) with Bonferoni Post 
Tests or Student's t-Tests (at specific time points). 
Figure 3.1 - Regulation of gene expression by PPARs (Binding of PPAR/Retinoid 
Nuclear Receptor Family) modified from (Reddy and Hashimoto 2001). The PPAR/RXR 
family is involved in controlling gene transcription at the nuclear level. Abbreviations: 
FA - fatty acid; PPAR - peroxisome proliferator-activated receptor; Pa - PPARa; RXR -
retinoid-X receptor; CRC - corepressor complex; HDACs - histone deacetylases; PPRE 
- PPAR response element; CAC - coActivator complex; HATs - histone 
acetyltransferases. 
Figure 3.2 In vitro experimental approach utilized in the expression of PPARa in MIN6 
cells (in vitro). Abbreviations: PPARa - peroxisome proliferator-activated receptor 
alpha; MIN6 - mouse insulinoma cell line; BSA - bovine serum albumin; GSIS -
glucose-stimulated insulin secretion. 
Figure 3.3 In vivo experimental approach characterizing the physiological effects of 
overexpressing PPARa in the pancreatic P-cells of C57B16 mice in vivo. Four month old 
male C57B16 mice were infected with either dsAAV8-RIP-eGFP (p-eGFP-HFD) or 
dsAAV8-RIP-PPARa and placed on high-fat diet for 16 weeks. Abbreviations: dsAAV8 
- double stranded adeno-associated virus serotype 8; RIP - rat insulin promotor; eGFP -
enhanced green fluorescent protein; PPARa - peroxisome proliferator-activated receptor 
alpha; FBG - fasted blood glucose; HFD - high-fat diet; ip - intraperitoneal. 
Figure 3.4 Overexpression of PPARa in MIN6 cells. Overexpression of PPARa in MIN6 
cells occurs at physiological levels (A) and upregulates expression of CPT1 with 
palmitate treatment (B). Overexpressing PPARa in MIN6 cells did not change insulin 
secretion when stimulated with high levels of glucose without palmitate (C). 
Abbreviations: PPARa - peroxisome proliferator-activated receptor alpha; MIN6 -
mouse insulinoma cell line; eGFP - enhanced green fluorescent protein; CPT1 - carnitine 
palmitoyl transferase-1; LCAD - long-chain acyl-coA dehydrogenase; UCP2 -
uncoupling protein-2; AOX - acyl-CoA oxidase. Mean values with standard error of 
mean are shown. Statistical significance was determined by 2-way ANOVA with 
Bonferoni Post Tests or Student's T-Tests. *P<0.05, **P<0.01, ***P<0.001, 
****P<0 oooi. 
Figure 3.5 (A) PPARa is overexpressed in the cytoplasm and nuclei (arrows) of P-
PPARa-HFD compared to P-eGFP-HFD controls. (B) Overexpression of PPARa in 
pancreatic P-cells of obese mice improved oral glucose tolerance (2g/kg D-glucose) 
compared to obese controls, with glucose tolerance similar to age-matched, chow mice. 
(C) Over time, no significant difference between 4 hr fasted blood glucose was observed. 
(D) PPARa overexpression did not affect body weight. (E), nor was insulin sensitivity 
affected (1U insulin/kg). Abbreviations: PPARa - peroxisome proliferator-activated 
receptor alpha; eGFP - enhanced green fluorescent protein; FBG - fasted blood glucose; 
HFD - high-fat diet. P-eGFP-HFD n=6, P-PPARa-HFP n=8. Mean values with SEM are 
shown. Statistical significant variation was determined by 2-way ANOVA with 
Bonferoni Post Tests or Student's T-Tests. *P<0.05, **P<0.01, ***P<0.001. 
Figure 3.6 Overexpression of PPARa in pancreatic P-cells shows a trend towards 
improved glucose tolerance over time (2g D-glucose/kg). Oral glucose tolerance tests 
over time (A) Baseline, (B) 1-month post-infection, (C) 2-months post-infection, (D) 3-
months post-infections (E) 4-months post infection. Abbreviations: PPARa - peroxisome 
proliferator-activated receptor alpha; eGFP - enhanced green fluorescent protein; FBG -
fasted blood glucose; HFD - high-fat diet. p-eGFP-HFD n=6, p-PPARa-HFP n=8. Mean 
values with SEM are shown. Statistical significant variation was determined by 2-way 
ANOVA with Bonferoni Post Tests. *P<0.05, **P<0.01, ***P<0.001. 
Figure 3.7 Overexpression of PPARa in pancreatic p-cells maintains 1st phase insulin 
secretion in C57B16 mice on high-fat diet compared to obese controls. Glucose-
stimulated insulin secretion (A) but not overnight and refeed insulin levels (B) was 
significantly affected. Additionally, overexpression of PPARa in pancreatic P-cells did 
not change islet morphology or P-cell or a-cell mass (C) when compared to obese 
controls. Abbreviations: PPARa - peroxisome proliferator-activated receptor alpha; eGFP 
- enhanced green fluorescent protein. P-eGFP-HFD n=6, P-PPARa-HFP n=8. Mean 
values with SEM are shown. Statistical significant variation was determined by 2-way 
ANOVA with Bonferoni Post Tests or Student's T-Tests. *P<0.05, **P<0.01, 
***p<0 001. Images taken at 20x magnification. Scale bar 50p.m. 
Figure 3.8 Overexpression of PPARa in pancreatic P-cells does not cause changes in 
peripheral tissue mass on HFD. Abbreviations: PPARa - peroxisome proliferator-
activated receptor alpha; eGFP - enhanced green fluorescent protein; HFD - high fat 
diet; scWAT - subcutaneous white adipose tissue; gWAT - gonodal white adipose tissue. 
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Figure 4.1 Comparing male C57B16 littermate controls to db/db (A) and ob/ob (B) mice. 
Mice purchased from JAX laboratories at four weeks of age. Images from Jackson 
Laboratories website: http://iaxmice.iax.org [electronic] accessed Dec 15 2011. 
Figure 4.2 Overexpression of PPARa in p-cells of genetically obese mice (db/db) did not 
improve glucose homeostasis. (A) Fast and fed blood glucose levels. (B) body weight, 
(C) plasma insulin levels, and (D) insulin sensitivity (0.75U/kg insulin for wild-type 
mice; 1.5U/kg insulin for db/db mice) in db/db mice. P-eGFP-db/db n=7, p-PPARa-
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db/db n=6. Mean values with SEM are shown. Statistical significant variation was 
determined by 2-way ANOVA with Bonferoni Post Tests. *P<0.05, **P<0.01, 
***P<0.001. 
Figure 4.3 Overexpression of PPARa in P-cells of genetically obese mice (db/db) does 
not affect islet morphology of insulin immuno-positive area. Abbreviations: INS -
insulin; GLC - glucagon. Images taken at 20x magnification. Scale bar 50nm. 
Figure 4.4 Overexpression of dsAAV8-RIP-eGFP in P-cells of genetically obese mice 
(db/db) is targeted to the p-cells and not a-cells of pancreatic islets. Abbreviations: INS -
insulin; GLC - glucagon; GFP - green fluorescent protein. Images taken at 20x 
magnification. Scale bar 50|im. 
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CHAPTER 1 
A lipotoxic approach to understanding the link between 
obesity and type 2 diabetes 
1 
1.1 INTRODUCTION 
1.1 General introduction to obesity 
Obesity is the number one risk factor for developing type 2 diabetes (T2D) 
(Smyth and Heron 2006); however, the physiological mechanisms underlying this 
association is not fully understood. Obesity results from chronic positive energy balance 
with subsequent increase in triglyceride (TG) storage in adipose tissue (van Herpen and 
Schrauwen-Hinderling 2008). In addition to T2D, obesity is a risk factor for numerous 
diseases including and not limited to: insulin resistance, cardiovascular disease, cancer, 
osteoarthritis, and non-alcoholic fatty liver disease (Kahn et al. 2006; Shoelson et al. 
2007; van Herpen and Schrauwen-Hinderling 2008; Kusminski etal. 2009). Recently, 
rates of obesity, including childhood obesity, have reached epidemic proportions around 
the world (Deckelbaum and Williams 2001; Smyth and Heron 2006); where it has been 
estimated that obesity and its comorbidities are responsible for approximately 300,000 
deaths annually (Dixon 2010). Therefore it is not a surprise that obesity is associated 
with a plethora of complications resulting in long term suffering for patients and huge 
economic burdens to health care systems around the world (Dixon 2010). 
Adipose tissues comprise a complex organ composed of adipocytes, vascular 
tissue, and immune cells that has the ability to expand and proliferate to meet fat storage 
needs (Gray and Vidal-Puig 2007). In healthy individuals, adipocytes are responsible for 
the storage of fats as TGs and additionally act as endocrine cells regulating fat mass, 
nutrient homeostasis and immune response (Spiegelman 1998; Rosen and Spiegelman 
2006). As seen in figure 1.1, adipocytes are depots for storing energy in the form of TGs 
which are 
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Figure 1.1 The adaptability of adipose tissue and its role as a endocrine organ - modified 
from (Gray and Vidal-Puig 2007; Shoelson et al. 2007). Healthy adipose tissue is 
involved in metabolic homeostasis through the production and secretion of adipokines 
(TNF-a, IL-6, MCP-1, PAI-1, leptin, adiponectin and resistin), as well as the storage of 
TGs. When the storage capacity of the adipocytes is overloaded, as seen in obesity, lipids 
spill-over and accumulate in the surrounding non-adipose tissues. This increase in 
adiposity also alters the adipokine profile.TNF-a -Tumor Necrosis Factor alpha; IL-6 -
Interleukin 6; PAI-1 - Plasminogen Activator Inhibitor-1; MCP-1 - Monocyte 
Chemoattractant Protein-1; TGs - triglycerides 
3 
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broken down into glycerol and fatty acids (FAs) when metabolic demand is increased and 
glucose stores are limited (Sethi and Vidal-Puig 2007). Healthy adipocytes have the 
ability to proliferate and undergo hypertrophy (Fig. 1.1) to accommodate the storage of 
excess lipids in times of over nutrition (Gray and Vidal-Puig 2007). In the non-obese 
state, adipocytes are continuously fluctuating between storage and lipolysis of TGs and 
FFAs to maintain lipid homeostasis (Greenberg et al. 2011). Lipolysis is the finely 
orchestrated regulation of lipid metabolism, controlled by various lipases including: 
hormone sensitive lipase (HSL), lipoprotein lipase (LPL) and adipose triglyceride lipase 
(ATGL) (Arner 2005; Carmen and Victor 2006; Haemmerle et al. 2006); where these 
lipases catalyze the hydrolysis of ester linkages in TGs and diacylglycerols (DAGs) to 
produce FFAs and glycerol (Arner 2005; Carmen and Victor 2006). Moreover, the liver 
is a primary organ involved in lipid metabolism, responsible for the production of 
cholesterols, TGs and lipoproteins (van Herpen and Schrauwen-Hinderling 2008). A 
recent study from Haemmerle and colleagues (2006) showed that a decrease in FA 
availability leads to increased glucose metabolism in adipose tissue and skeletal muscle 
in ATGL knockout mice (Haemmerle et al. 2006). Furthermore, this study showed that 
ATGL is a key mediator in TG catabolism in both adipose and non-adipose tissues 
(Haemmerle et al. 2006). 
Increased levels of basal lipolysis has been observed in obesity, and is thought to 
be due to ineffective actions of insulin (unable to inhibit lipolysis), increased levels of 
circulating leptin, and tumor necrosis factor-a (Duncan et al. 2007). Therefore, the 
inability to inhibit lipolysis in both the fed and fasted state greatly contributes to 
increased circulating levels of TGs and FAs, as well as disruption of TG storage in 
5 
adipocytes (Langin et al. 2005; Duncan et al. 2007). In the obese state, when the storage 
capacity of adipose tissue is challenged, excess lipids "leak" out of the adipocytes into 
the circulation. This "spillover" of lipids, results in elevated circulating levels of FAs and 
TGs contributing to abnormal accumulation of lipids in non-adipose tissues such as 
skeletal muscle, liver, heart and J3-cells of the pancreas (Eldor and Raz 2006; van Herpen 
and Schrauwen-Hinderling 2008), a phenomenon known as lipotoxicity. 
1.2 General introduction to lipotoxicity 
Lipid accumulation as a result of lipid spillover has been associated with having 
toxic effects in peripheral, non-adipose tissues; a term referred to as lipotoxicity. It 
should also be noted that lipotoxicity can also affect individuals who suffer from 
lipodistrophy (lack of natuarally occurring adipose tissue), as there is no natural storage 
depot for circulating FAs and TGs, therefore lipids begin to accumulate in non-adipose 
tissues (Unger 2002). 
Increased lipid accumulation in tissues such as liver, skeletal muscle, heart and 
pancreas have been associated with a plethora of dysfunctional consequences. Lipotoxic 
effects in skeletal muscle and liver have been associated with low-grade inflammation 
and insulin resistance; in addition the development of non-alcoholic fatty liver disease is 
also thought to be a consequence of lipotoxicity in the liver (van Herpen and Schrauwen-
Hinderling 2008; Chavez and Summers 2010). Abnormal lipid accumulation in the heart 
and vasculature has been associated with cardiomyopathy, heart failure ("lipotoxic 
heart"), inflammation and endothelial dysfunction (contributing to the progression of 
atherosclerosis) (Unger 2002; van Herpen and Schrauwen-Hinderling 2008; Imrie et al. 
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2010; Wende and Abel 2010). It is well established that lipid accumulation within the 
pancreatic P-cells has been associated with insulin resistance, P-cell dysfunction, and P-
cell failure (Prentki and Nolan 2006; Summers 2006; van Herpen and Schrauwen-
Hinderling 2008; Virtue and Vidal-Puig 2010). Insulin is responsible for activating LPL 
activity in adipocytes for increased FA storage, and decreases LPL activity in skeletal 
muscle (Farese et al. 1991; Lewis et al. 2002). In the obese state, LPL activity is 
inhibited in the adipocytes causing the storage of FAs to be distributed to the circulation 
and non-adipose tissues (Sadur et al. 1984; Yost et al. 1995; Lewis et al. 2002), thus 
insulin resistance is a "double-edged sword" further contributing to the vicious lipotoxic 
cycle. Lipotoxicty and its role in P-cell dysfunction will be discussed later in this review. 
There has been great debate in the literature as to whether it is the quantity or 
quality of lipid species that has the most detrimental toxic effects in non-adipose tissues. 
Ceramides and sphingolipids have been lipid species of intense study in obesity research 
as they have been found to be involved in inhibiting glucose uptake in cells as well as 
inducing oxidative stress (Holland et al. 2007). Ceramides have also been linked to 
influencing the regulation of various adipokines such as TNF-a (Summers 2006), as well 
as contributing to apoptosis through increased ROS production and activation of the NF-
KB pathways (Kusminski et al. 2009; Chavez and Summers 2010) inducing p-cell 
dysfunction and insulin resistance, as well as endothelial inflammation and dysfunction. 
Moreover it has also been shown that ceramides impair the translocation of GLUT4 on 
cellular membranes in muscle, adipose and liver tissue (JeBailey et al. 2007; Hoehn et al. 
2008). Combined, ceramide and sphingolipid species have been implicated as the toxic 
intermediates involved in lipotoxic accumulation in non-adipose tissues (Chavez et al. 
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2003; Summers 2006; Wende and Abel 2010), as well as contributing to inflammation 
through increased ER stress and reactive oxygen species (ROS) (Wende and Abel 2010). 
Additionally, adipokines, in association with the lipotoxic effects of lipid 
accumulation in non-adipose tissues, exacerbates the use of non-oxidative pathways 
(Kusminski et al. 2009) resulting in cellular dysfunction and apoptosis (Gray et al. 2006; 
Summers 2006). Thus the combination of lipotoxicity and pro-inflammatory mediators 
contribute to insulin resistance, oxidative stress, and P-cell dysfunction (Cave et al. 
2008). 
1.3 Changes in adipokine profiles: role in p-cell dysfunction and insulin resistance 
Until recently, it was thought that the primary role of adipose tissue was energy 
homeostasis and a depot for fat storage (Ahima 2006). It wasn't until the discovery of 
leptin, an adipocyte derived hormone, that adipose tissue was regarded as an endocrine 
organ (Zhang et al. 1994; Kershaw and Flier 2004; Ahima 2006; Friedman 2010). Leptin 
has been identified to play a role in fuel metabolism in peripheral tissues (Suzuki et al. 
2007), appetite suppression and reduced fat mass (Schroeder-Gloeekler et al. 2007), FA 
oxidation in skeletal muscle (Muoio and Lynis Dohm 2002), and glucose metabolism 
(Huynh et al. 2010). A more in-depth review of leptin will be covered in chapter 4. 
The adipose tissue acts as an endocrine organ producing and secreting adipocyte 
derived hormones (adipokines) that play a role in metabolic regulation (Gray and Vidal-
Puig 2007). It has been well established that adipokine production and secretion change 
in the obese state (Gray and Vidal-Puig 2007) as seen in figure 1.1. The change in 
adipokine profiles in the obese state is thought to contribute to a low-grade inflammatory 
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state and insulin resistance (Eldor and Raz 2006; Gray and Vidal-Puig 2007; Lago et al. 
2007). Recent studies have shown that adipokines involved in metabolic homeostasis 
include: tumor necrosis factor-a (TNF-a), interluekin-6 (IL-6), monocyte chemoattractant 
protein-1 (MCP-1), plasminogen activator inhibitor-1 (PAI-1), resistin, adiponectin and 
leptin (Shoelson et al. 2006). 
An increase in TNF-a, IL-6, MCP-1, PAI-1, and resistin as seen in obesity 
promotes a pro-inflammatory state that contributes to developing insulin resistance and 
also potentiates vascular disease (Esposito et al. 2006; Shoelson et al. 2007). Unlike the 
other pro-inflammatory adipokines, adiponectin which is reduced in the obese state, has 
anti-inflammatory, and insulin-sensitizing properties and has been found to be inhibited 
by TNF-a and IL-6 in obese states (Esposito et al. 2006; Lago et al. 2007). Likewise, 
leptin acts on the central nervous system and peripheral tissues to reduce fat stores by 
suppressing appetite, increasing metabolic rate, and activating thermogenesis (Muoio and 
Lynis Dohm 2002; Ceddia 2005; Unger 2005; Zhao et al. 2006; Gray and Vidal-Puig 
2007; Friedman 2010), it also functions in glucose metabolism, cytokine secretion, 
phagocytosis, and angiogenesis (Otero ct al. 2006; Lago et al. 2007). This ultimately 
contributes to localized disturbances in metabolic pathways contributing to increased 
macrophage infiltration, insulin resistance, and endothelial damage (Laclaustra et al. 
2007; Shoelson et al. 2007). Thus, obesity is a state of heightened inflammation, a 
process that contributes to the development of obesity-induced insulin resistance; 
therefore, these inflammatory mediators and the pathways in which they activate could be 
potential targets for therapeutic interventions or prevention for obesity induced insulin 
resistance and (3-cell dysfunction. 
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Lipotoxicity and changes in adipokine profiles have been discussed as obesity 
related hypotheses as contributing factors to insulin resistance and P-cell dysfunction. 
The remainder of my thesis will focus on the lipotoxic hypothesis and its role in P-cell 
dysfunction and failure in the progression of obesity-induced T2D. 
1.4 The pancreas: insulin secretion and action 
The pancreas functions as both an exocrine and endocrine organ; with the 
endocrine pancreas responsible for the production and secretion of several hormones that 
regulate carbohydrate metabolism, including insulin. The endocrine pancreas contains 
approximately one million islets composed of several cell types (a-cells, P-cells, 8-cells, 
F-cells, and e-cells). The pancreatic P-cells produce and secrete insulin promoting 
glucose uptake and storage within skeletal muscle and adipose tissue and glucose 
production and storage in liver. In addition to its role in regulating glucose metabolism, 
insulin also regulates lipid metabolism promoting the storage of fat within adipose tissue 
(Evans et al. 2004; Wellen and Hotamisligil 2005; Razani et al. 2008), and acting on the 
brain, specifically the hypothalamus to regulate energy balance by reducing food intake 
(Choudhury et al. 2005; Kahn et al. 2006). 
As shown in figure 1.2, nutrient stimuli such as glucose, amino acids and FFAs, 
get shuttled into the P-cell through their respected transporters. Once inside the cell, the 
glucose and amino acids (via pyruvate) undergo glycolysis in the mitochondria increasing 
intracellular levels of ATP (Las et al. 2006; Nolan et al. 2006). The increase in 
intracellular ATP causes ATP-sensitive K+ channels to close, depolarizing the cell and 
increasing membrane potential; subsequently opening Ca2+ channels and causing an 
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influx of Ca2+ into the cell (Henquin 2000; Nolan et al. 2006). The increase in 
intracellular Ca2+, activates a calmodulin cascade and release of insulin from secretory 
granules that undergo exocytosis (Henquin 2000) (Fig 1.2). Additionally, the binding of 
FFAs to the free fatty acid receptor-1/G-coupled receptor-40 (FFAR1/GPR40) receptors 
on the P-cell membrane causes an increase in intracellular Ca2+ further stimulating the 
calmodulin cascade and release of insulin (Prentki and Nolan 2006) (Fig 1.2). 
Insulin secretion can also be stimulated by the parasympathetic nervous system 
through the binding of acetylcholine (ACh) to the muscarinic receptor (M2) on the p-cell 
(Kahn et al. 2006). Binding of ACh can act through either the protein kinase C (PKC) 
pathway via phospholipase C or through phosphatidylinositol 3-kinase (PI-3K) and 
subsequent increase in Ca2f to stimulate insulin secretion (Kahn et al. 2006; Nolan and 
Prentki 2008). Moreover, the insulin secretion from the P-cell is also stimulated 
hormonally through the binding of incretin hormones such as glucagon-like peptide 1 
(GLP-1), glucagon-dependent insulinotropic peptide (GIP), pituitary adenylate cyclase-
activating polypeptide (PACAP), and vasoactive intestinal polypeptide (VIP) (Inagaki et 
al. 1996; Yamamoto et al. 2003; Hoist and Gromada 2004; Kieffer 2004). For example, 
binding of GLP-1 results in an increase in intracellular cyclic adenosine monophosphate 
(c AMP) causing the stimulation of protein kinase A (PKA) and subsequent closure of K+ 
channels and depolarization of the p-cell (Kieffer 2004; Kahn et al. 2006); thus 
contributing to the influx of Ca2+ and increase in intracellular Ca2f. 
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Figure 1.2 Schematic representation of insulin secretion in the pancreatic p-cell by 
endogenous stimuli - modified from (Boron and Boulpaep 2005). Nutrient stimuli (such 
as glucose, amino acids and FFAs) get shuttled into the p-cell through their respective 
transporters. Once inside the cell, through their respective pathways, the stimuli cause an 
influx of Ca2+ into the cell and release of insulin (via exocytosis of insulin secretory 
granules). Once secreted insulin binds to insulin receptors and increases glucose uptake 
and storage as well as increasing fat storage in adipose tissue. Abbreviations: +++ -
depolarization; GLUT2 - glucose 2 transporter; aa - amino acids; K+ channel; Ca2+ 
channels; ATP - adenosine triphosphate; FFAR1/GPR40 - free fatty acid receptor-l/G-
coupled receptor-40; FFA - free fatty acid. 
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Once secreted, insulin binds to insulin receptors on peripheral tissues such as 
muscle, liver and fat tissue, and stimulates tyrosine kinase activity and subsequent 
phosphorylation of insulin receptor substrates 1 (IRS-1) and IRS-2 (Aspinwall et al. 
2000). This phosphorylation leads to activation of the phosphatidylinositol 3-kinase 
(PI3K) pathway and production of downstream intermediates (Summers 2006). One 
example of a downstream target of this insulin signal transduction cascade is stimulation 
of the translocation of glucose transporter 4 (GLUT4), expressed in both muscle and 
adipose tissue, from the cytoplasm to the cell membrane allowing the influx of glucose 
into the cell for glycolysis or storage (Rose and Richter 2005; Summers 2006) (Fig 1.2). 
Another molecular action of insulin signaling is its ability to increase the action of 
lipoprotein lipase (LPL) to promote the storage of FA within the adipocytes (Razani et al. 
2008). As highlighted above, insulin secretion and insulin signaling are complex 
pathways regulated by many stimuli and affecting many molecular targets; therefore 
disruptions to the signal transduction pathways in a variety of cell types can be 
detrimental to whole-body carbohydrate metabolism. 
There is great debate in the literature about what comes first in the pathogenesis 
of T2D: insulin resistance or P-cell dysfunction? Both etiologies are characteristic of 
obesity-induced T2D and P-cell dysfunction required for the progression to T2D. Insulin 
resistance is a hallmark of the pre-diabetic state and is thought to be a critical 
pathophysiological event in the development of obesity-induced diabetes. As discussed 
above, changes in adipokine secretion, lipid storage and inflammatory profiles in obesity 
induce peripheral insulin resistance, resulting in compensatory hypersecretion of insulin 
from pancreatic P-cells to maintain glucose homeostasis (Prentki and Nolan 2006). If p~ 
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cell function cannot maintain compensatory increases in insulin secretion impaired 
glucose tolerance results and T2D develops (Fig. 1.3) (Gehrmann et al. 2010; Giacca et 
al. 2011). Hyperglycemia itself can also contribute to the activation of inflammatory 
pathways involving NF-KB and PKC through increased production of reactive oxygen 
species (ROS) (Lau et al. 2005) further contributing to p-cell dysfunction. Furthermore, 
ineffective insulin action effects lipoprotein metabolism due to a decrease in LPL action 
and decreased suppression of lipolysis resulting in increased small dense low-density 
lipoprotein (LDL) and decreased high-density lipoprotein (HDL) levels (Razani et al. 
2008). 
1.5 Pancreatic p-cell dysfunction: the lipotoxic hypothesis 
As discussed above, acute exposure of p-cells to free fatty acids (FFAs) is a 
physiological stimulus for normal insulin secretion and P-cell function (Nolan et al. 
2006). However, it is well established that chronic exposure of p-cells to high levels of 
FFAs is detrimental to P-cell health (Lee et al. 2007; Giacca et al. 2011). For example, 
Kim and colleagues (2003) showed that reducing circulating lipid in a genetic mouse 
model of insulin resistance and diabetes (the MKR mouse model - skeletal muscle-
specific impairment of IGF-1 receptor) using a hyperlipidemic agent (a fibrate) improved 
the diabetic state of this animal; suggesting that high circulating is associated with p-cell 
dysfunction (Kim et al. 2003). Excessive amounts of FFAs within the P-cell have been 
shown to interrupt glucose-stimulated insulin secretion and increase rates of apoptosis 
(Bonora 2008; Morgan 2009). 
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Figure 1.3 Obesity is known to cause insulin resistance and P-cell dysfunction - modified 
from (Kasuga 2006; Shoelson et al. 2007). Adipose tissue in the obese state contributes to 
altered adipokine profiles, and lipid accumulation in non-adipose tissues, causing insulin 
resistance and P-cell dysfunction. In the insulin resistant state, pancreatic islets make 
more insulin (hyperinsulinemia) to maintain normal glucose homeostasis. The islets 
"tire" from over-producing insulin and eventually fail resulting in T2D. 
Abbreviations: T2D - type 2 diabetes. 
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For instance, increased levels of FAs within the P-cell have been shown to modify the 
expression of uncoupling protein-2 (UCP2) which is linked to the subsequent decrease in 
ATP production (van Herpen and Schrauwen-Hinderling 2008), disrupting insulin 
secretion (Poitout and Robertson 2008). 
Mediators of FAs including long-chain acyl-CoAs (LC-CoA) have been 
implicated in hyperpolarizing the p-cell (reducing the influx of Ca2+ into the P-cell) as 
well as downregulating the PKC pathway, further disrupting the exocytosis of insulin 
(van Herpen and Schrauwen-Hinderling 2008). Moreover, FFAs have also been linked to 
increased apoptosis by enhancing ROS production and cellular stress (Prentki and Nolan 
2006) further contributing to P-cell dysfunction. Interestingly, studies involving GPR40 
knockout mice showed a reduction in hyperglycemia, hyperinsulinemia when on normal 
chow or high fat diet (Steneberg et al. 2005); thus providing further evidence that FAs 
shuttled into the p-cell, in excess, can have detrimental effects on P-cell function and 
whole-body carbohydrate metabolism. More recent studies involving the GPR40 
knockout mouse have shown that in response to endogenous stimuli in both the fasted 
and fed states, insulin secretion is impaired in these mice (Latour et al. 2007; Alquier et 
al. 2009). Combined, these studies have suggested GPR40 signaling pathways to be 
responsible for the potentiating effects of FAs on insulin secretion (Latour et al. 2007; 
Alquier et al. 2009). 
There is increasing evidence that the type of lipid accumulating within the P-cell 
may affect toxicity and p-cell failure (Virtue and Vidal-Puig 2010). In vitro studies 
involving the INS-IE or MIN6 p-cell lines have shown higher rates of apoptosis when 
treated with the saturated FA palmitate versus the unsaturated FA oleate (Furukawa et al. 
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1999; Karaskov et al. 2006; Frigerio et al. 2010). For example, the accumulation of 
diacylglycerols (DAGs) and ceramides in pancreatic p-cells and peripheral tissues have 
been shown to cause detrimental effects and may be key intermediates in lipotoxic 
induced p-cell failure and insulin resistance (Chavez and Summers 2010; Virtue and 
Vidal-Puig 2010). Itani and colleagues (2002) have suggested that DAGs, rather than 
ceramides, were primary mediators of lipid-induced insulin resistance using lipid-
infusion studies in whole animals (Itani et al. 2002). Conversely, Chavez and colleagues 
(2003) have shown endogenous ceramides were required for inhibitory effects of long-
chain saturated fatty acids on insulin signaling (Chavez et al. 2003) and Holland and 
colleagues (2007) further showed that modulating ceramide levels utilizing myriocin (a 
potent inhibitor of sphingosine biosynthesis) in obese rodents, ameliorates insulin 
resistance and subsequent development of diabetes (Holland et al. 2007). Therefore the (3-
cell is an attractive target for improved therapeutics and new treatment paradigms. 
This introductory chapter has highlighted the effects of obesity on peripheral 
insulin resistance and p-cell dysfunction through the "lipotoxic" accumulation of lipids. 
To summarize, increases in adiposity causes changes in adipokine profiles and levels of 
FAs accumulating and being metabolized in non-adipose tissues. These lipotoxic 
disturbances have a strong association with increased rates of insulin resistance and P-cell 
dysfunction in obese individuals through the disruption of various signaling pathways 
involved. The impact of lipotoxic lipid accumulation and metabolism in pancreatic P-
cells under conditions of obesity is the focus of my thesis. My work will help elucidate 
the mechanisms involved in P-cell lipotoxicity and may identify this area as a target for 
improved therapeutics and treatment paradigms. 
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As such, manipulating how lipids accumulate within P-cells may be a plausible 
approach to reducing lipotoxicity and preserving P-cell function. Peroxisome 
proliferator-activated receptors (PPARs) are a group of nuclear transcription factors 
involved in lipid metabolism (Chinetti et al. 2000; Lee et al. 2007); where PPARa has 
been identified as a key regulator of genes involved in P-oxidation, FA uptake, and co-
oxidation (Lee et al. 2007). PPARa will be discussed in detail in chapter 3. Using an 
adeno-associated virus serotype 8 (dsAAV8; discussed in detail in chapter 2) for targeted 
overexpression of PPARa in the pancreatic P-cells, my project aims to manipulate lipid 
metabolism in P-cells of mice on high-fat diet; with the expectation that overexpression 
of PPARa would affect whole-animal carbohydrate metabolism. Moreover, this would 
allow us to develop and test the lipotoxic hypothesis in an in vivo model of diet-induced 
p-cell lipotoxicity and T2D. Furthermore, we will be able to look at what subset of 
PPARa target genes (Acyl-CoA oxidase (AOX), carnitine palmitoyl transferase-1 
(CPTl), long chain acyl-coA dehydrogenase (LCAD), and uncoupling protein-2 (UCP2)) 
are involved in P-oxidative pathways within the P-cells; thus allowing us to elucidate 
possible mechanisms involved in protecting the p-cell from lipotoxic lipid accumulation 
in an in vivo model. 
1.6 Study objectives 
Lipid accumulation within the p-cell of the pancreas is a key contributor to 
inhibition of insulin secretion and P-cell apoptosis in the development of T2D in obesity. 
As such, manipulating how lipids accumulate within p-cells may be a plausible approach 
to reducing lipotoxicity and preserving p-cell function. The main objectives of this study 
are: 
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1. To establish whether associated-adeno virus serotype 8 (dsAAV8) is an 
effective and feasible targeted gene delivery tool to generate in vivo animal 
models overexpressing proteins of interest specifically in pancreatic P-cells to 
study lipotoxcity in obesity induced T2D (Chapter 2). 
2. To characterize the in vivo effects of PPARa overexpression in pancreatic P-
cells on lipotoxicity in a diet-induced obese model of T2D (Chapter 3). 
3. To characterize the in vivo effects of PPARa overexpression in pancreatic P-
cells on lipotoxicity in a genetic model of severe obesity and T2D (db/db 
mouse) (Chapter 4). 
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Utilizing dsAAV8 as a Tool to Overexpress Proteins Specifically in the Pancreatic P-
Cell In Vivo 
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2.1 INTRODUCTION 
Transgenic or knockout mouse models have been used to study various pathways 
and mechanisms involved in human diseases. Transgenic models are tools utilized to 
study gene function; specifically they provide in vivo models to examine the effects of 
overexpressing or knocking out genes of interest proving to be a critical link between 
bedside and bench (Miesfeld 1999). Additionally, the development of the Cre/loxP 
system for animal transgenics has allowed for infinite possibilities for conditional 
knockouts including developmental stage and tissue-specific gene knockout (Nagy 2000). 
As outlined in chapter 1, obesity has been implicated in increasing adiposity in non-
adipose tissues such as the p-cells of the pancreas contributing to insulin resistance, p-cell 
dysfunction and development of T2D (Kasuga 2006; Prentki and Nolan 2006; van 
Herpen and Schrauwen-Hinderling 2008). Thus making the P-cell an ideal target for 
elucidating the mechanisms involved in p-cell lipotoxicity in obesity-induced T2D. 
Therefore mouse models for p-cell-specific overexpression or gene knockouts are very 
relevant to the remainder of this study. 
Tissue specific promoters such as the mouse insulin promoter (MIP) and rat 
insulin promoter (RIP) have been used to develop P-cell specific transgenic mouse 
models (Gannon et al. 2000; Hara et al. 2003; Dahlhoff et al. 2011) by driving the gene or 
protein of interest directly to the insulin producing P-cells of the pancreas. It should be 
noted that the human genome contains a single copy of the insulin gene, whereas two 
variations are found in the rat (RIP1 and RIP2) (Odagiri et al. 1996; Hay and Docherty 
2006). RIP1 and RIP2 vary in size (448bp and 668bp respectively), however they both 
target the P-cells of the pancreas (Gannon et al. 2000; Hay and Docherty 2006). Hara et 
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al. (2003) developed transgenic mice expressing enhanced green fluorescent protein 
(eGFP) in pancreatic P-cells under the direction of the MIP (Hara et al. 2003). In 
addition, Hara and colleagues (2003) were able to show that under the control of MIP, 
eGFP was targeted to the P-cells and not the a-cells of the pancreas utilizing FACS to 
sort isolated islets (Hara et al. 2003), further confirming site-specific expression. 
It should be noted that utilizing the RIP to target the P-cells of the pancreas in a 
RIP-Cre transgenic has been associated with "extrapancreatic" expression in neural 
tissues of the brain (Gannon et al. 2000; Dahlhoff et al. 2011). Choudhury and 
colleagues (2005) were able to show expression of eGFP in the hypothalamic and 
forebrain neurons in addition to the P-cells of the pancreas in their RIPCreZEG 
transgenic mouse (Choudhury et al. 2005). This neuronal expression utilizing RIP-Cre 
transgenic mice was further supported by the results obtained by Choi and colleagues 
(2008) where RIPCre+Pte«fl,fl mice were found to be PTEN deficient in the insulin 
secreting neurons in the hypothalamus and not the p-cells of the pancreas (Choi et al. 
2008). Moreover, Gannon and colleagues (2000) expressed that caution needs to be 
exercised when using RIP2-Cre mice, as RIP2 directs expression of the gene of interest 
during embryogenesis in both the pancreas and brain, as well, the activation of RIP 
during early development may interfere with the populations of cells becoming P-cells 
(Gannon et al. 2000). All of this information needs to be taken into consideration when 
deciding if a transgenic mouse model is the most appropriate tool for P-cell-specific gene 
expression for in vivo overexpression studies. 
Novel methods involving the transfer of genes into specific tissues of interest 
using viral delivery have become more widely accepted and used in place of traditional 
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transgenic models. One emerging field is the use of adeno-associated viruses as a mode 
of viral gene delivery. Currently, three classifications of adeno-associated viruses exist: 
single stranded adeno-associated virus (AAV), recombinant adeno-associated virus 
(rAAV) and the double-stranded adeno-associated virus (dsAAV) (Wang et al. 2004; Wu 
et al. 2006); in addition there are several serotypes and hundreds of variations of AAV-
based vectors (Wu et al. 2006). 
Adeno-associated viruses are small, non-pathogenic, non-replicating, members of 
the Parvovirdiae family, requiring a helper virus for appropriate infection and site-
specific integration into tissues of interest (Wang et al. 2004; Inagaki et al. 2006; Wu et 
al. 2006). AAVs also exhibit low immune response, as well they can be used to transfect 
both dividing and non-dividing cell types (Gao et al. 2002; Gaddy et al. 2010; Riedel et 
al. 2010), making them an ideal and efficient tool for viral-mediated gene delivery. 
Tissue-specific delivery of the AAVs is dependent on the serotype capsid with which it is 
associated (Inagaki et al. 2006). Serotypes and their tissue specificity include: AAV1 
(CNS, skeletal muscle and adipose tissue), AAV2 (kidney), AAV4 (CNS, and 
photoreceptors), AAVS (CNS, and photoreceptors), AAV6 (skeletal muscle), AAV7 
(skeletal muscle), AAV8 (skeletal muscle, liver, heart and pancreas) and AAV9 (skeletal 
muscle, liver, lung) (Chao et al. 2000; Gao et al. 2002; Loiler et al. 2003; Wang et al. 
2004; Wu et al. 2006). Given AAV8 delivery is directed at tissues in the gut, therefore, 
site-specific delivery to the p-cells of the pancreas could be enhanced utilizing tissue 
specific promoters such as MIP or RIP (Wu et al. 2006). 
Based on the various tissue types dsAAVs can target as well as their low immune 
response, dsAAVs are becoming an increasingly attractive tool for gene therapy. 
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Recently, Gaddy and colleagues (2011) have utilized dsAAV8 driven by MIP to target 
interleukin-4 (IL-4) as well as combinations of glucagon-like peptide-1 and hepatocyte 
growth factor/NKl with IL-4 to the pancreatic P-cells in NOD mice (model of T1D) 
(Gaddy et al. 2011). Using dsAAV8, they were able to demonstrate that IL-4 as well as 
the various combinations (GLP-1 + IL-4 and NK1 + IL-4) reverse hyperglycemia in 
NOD mice through a single ip injection (Gaddy et al. 2011). Moreover, Montane and 
colleagues (2011) utilized dsAAV8 to target CCL22 (recruits Treg cells) to the p-cells of 
NOD mice, through an intraductal injection (Montane et al. 2011). Their results suggest 
that increasing expression of CCL22 in the pancreatic P-cells attenuates the autoimmune 
destruction of P-cells associated in T1D through the increased recruitment of Tregs 
(Montane et al. 2011). Combined, these studies show the remarkable potential of 
utilizing dsAAVs for human gene therapy. 
Double-stranded adeno-associated (dsAAV) viral vectors have been used as non­
invasive tools for tissue-specific gene delivery to pancreatic p-cells. Extensive in vivo 
studies were conducted administering eGFP with various AAV serotypes under the 
direction of MIP to C57B16 mice via intraperitoneal, intraductal, and intravenous 
injection (Wang et al. 2006). Wang and colleagues (2006) concluded that viral delivery 
via interperitoneal injections were as effective as intraductal and intravenous when viral 
dose was increase to 5x10" viral/genomes per mouse (Wang et al. 2006); moreover 
dsAAV8 was more effective than dsAAVl, dsAAV2, dsAAV5 and dsAAV6 when 
targeting the pancreatic p-cells (Wang et al. 2006). In addition gene expression in 
pancreatic islets was observed for four months post infection via intraperitoneal injection 
(Wang et al. 2006). More recently, Kieffer and colleagues (2011) have conducted long-
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term expression studies, showing expression of dsAAV8-MIP-eGFP in the pancreatic P-
cells one year post-infection (Kieffer, TJ - personal communication). 
Furthermore, under the direction of MIP, Wang and colleagues did not detect 
eGFP expression in brain tissue of infected mice (Wang et al. 2006), indicating that using 
dsAAV8-MIP or dsAAV8-RIP to target pancreatic P-cells is an effective method for gene 
delivery without crossing the blood brain barrier. It should be noted that previous studies 
have indicated that utilizing dsAAV8 under the direction of MIP or RIP may cross the 
BBB due to dsAAV8's ability to increase vascular permeability in endothelial cell lining 
of blood vessels (Inagaki et al. 2006; Wu et al. 2006); further studies investigating the 
vasculature leakiness of dsAAV8 is required. 
More recently, Gaddy and colleagues (2010) have been able to successfully 
overexpress eGFP within pancreatic P-cells without causing changes in body weight or 
carbohydrate metabolism utilizing dsAAV8 (Gaddy et al. 2010; Riedel et al. 2010). 
These studies demonstrate using dsAAV8-RIP-eGFP as a control vector for in vivo 
overexpression studies is an appropriate tool for viral-mediated tissue specific gene 
delivery. Moreover, the use of dsAAV8 allows for targeted gene delivery at any stage in 
the rodent's life; essentially providing a model of "inducible transgenics" without the 
complications associated with conventional transgenic mouse models. Additionally 
dsAAV8 can be delivered prior to or after a treatment such as high fat diet; as well it can 
be delivered to various mouse breeds including the "standard" C57B16 or various 
transgenic models including db/db or ob/ob mouse (to be discussed in chapter four). 
The objective of this study is to establish an in vivo model and protocol of viral-
mediated gene delivery in our lab. This study will serve as control for data collection and 
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analysis prior to characterizing the in vivo effects of dsAAV8-RIP-PPARa 
overexpression in p-cell lipotoxicity in a diet-induced obese model of T2D. 
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2.2 MATERIALS AND METHODS 
Mice. 
All animal studies were approved by the University of Northern British Columbia 
Animal Care and Use Committee (protocol number 2011-21). For all experiments, 6-
week-old, male, C57B16 mice were purchased from Charles River Laboratories 
(Wilmington MA, USA) unless otherwise stated. Mice were maintained on a 12 hr 
light/dark cycle and received standard rodent chow diet (Rodent LabDiet, 5001, Leduc 
AB, Canada) ad libitum unless otherwise stated. Mice were allowed to acclimatize to the 
animal facility for 1 week prior to performing any experimental procedures. Body weight, 
4hr fasted blood glucose (OneTouch Ultra, Lifescan, Burnaby BC, Canada), oral glucose 
tolerance tests (OGTT) and insulin tolerance tests (ITT) were performed prior to viral 
injections to assess baseline carbohydrate metabolism. 
Double-stranded adeno-associated virus serotype 8. 
dsAAV8 transfer vectors were designed utilizing the rat insulin 1 promoter (RIP) 
(410 bp) placed upstream of either a sequence encoding eGFP (720bp) or the PPARa 
(1407bp) open reading frame, followed by the SV40 polyadenylation signal. Complete 
RIP-eGFP (5328bp) and RIP-PPARa (6015bp) vectors were sent to Children's Hospital 
of Philadelphia (CHOP) Research Vector Core Services (Philadelphia PA, USA) for 
AAV8 virus preparation. 
Pancreatic p-cell specific expression of eGFP. 
At 8 wks of age, C57B16 mice were infected with dsAAV8-RIP-eGFP virus by ip 
injection (n=7; 5xl012 viral genomes/284 |il/mouse) (P-eGFP-Chow) and control mice 
(saline) were given an ip injection of saline (n=7; 284(il/mouse) (Gaddy et al. 2010; 
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Riedel et al. 2010) (Fig. 2.1). Body weights, glucose tolerance and insulin sensitivity 
were assessed prior to and three weeks post-infection. Three weeks post-infection 
animals were sacrificed and pancreas was collected and stored in 4% paraformaldehyde 
for immunohistological analysis. 
Insulin tolerance tests. 
Mice were fasted for 4hrs and given an ip injection of human synthetic insulin at 
0.75U/kg or l.OU/kg (Novolin Ge, Toronto ON, Canada). Blood was sampled (l-2|il) 
from the saphenous vein and blood glucose measured (mmol/L) at 10, 20 30, 60, and 120 
min post injection, using a handheld glucometer (OneTouch Ultra Lifescan, Burnaby BC, 
Canada). 
Oral glucose tolerance and glucose-stimulated insulin secretion. 
Mice were fasted for 16 hrs and given 2g/kg D-glucose by oral gavage. Blood 
(15-20(^1) was sampled at 5, 10 and 180 minutes post glucose gavage from the saphenous 
vein and blood glucose (mmol/L) measured in 1-2(^1 blood at 5, 10, 30, 60, 120 and 180 
minutes post gavage using a handheld glucometer (OneTouch Ultra Lifescan, Burnaby 
BC, Canada) (Huynh et al. 2010). 
Immunohistological analysis. 
Whole mouse pancreas were fixed in 4% paraformaldehyde, embedded in paraffin 
and sectioned (5^m); n=5 per group (Wax-it Histology Services; Vancouver BC, 
Canada). All sections were de-paraffinized in xylene, rehydrated in ethanol (100%, 95%, 
and 70%) and rinsed in lxPBS as described previously (Riedel et al. 2010). Sections 
were incubated with polyclonal primary antibody to rabbit anti-eGFP (1:500) (Al 1122, 
Invitrogen Molecular Probes, Carlsbad CA, USA), polyclonal guinea pig anti-insulin 
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(1:1000) (4011-0IF, Millipore, Billerica MA, USA) and a monoclonal primary antibody 
to mouse anti-glucagon (1:1000) (G2654, Sigma, Oakville ON, Canada) overnight. 
Appropriate secondary whole (heavy and light chain) antibodies conjugated to Alexafluor 
488 (A21206 or A21202) or 594 (A 11076 or A11032) (1:1000) (Invitrogen Molecular 
Probes, Carlsbad CA, USA) were used to detect primary antibody immunoreactivity. All 
samples were visualized using a fluorescent light microscope (Olympus BX61) and 
images analyzed using Cell Sens Software (Olympus, Markham ON, Canada). 
Western blot analysis. 
Hypothalamus, liver, intestine, and skeletal muscle samples were collected and 
flash frozen. Protein was extracted using RIPA buffer (Thermo Scientific, Rockford IL, 
USA) and quantified using a BCA assay (Thermo Scientific, Rockford IL, USA). Protein 
(30|4.g) was separated on a 12% SDS-PAGE gel and transferred to a PVDF membrane 
(Millipore, Billerica MA, USA). Membranes were blocked with 5% non-fat dry milk in 
TBS-Tween 20 followed by overnight incubations with a polyclonal primary antibody to 
rabbit anti-eGFP (1:1000) (A11122, Invitrogen Molecular Probes, Carlsbad CA, USA), a 
monoclonal primary antibody to mouse anti-P-Actin (A5441, Sigma, Oakville ON, 
Canada), or a monoclonal primary antibody to mouse anti-a-tubulin (1:3000) (T8203, 
Sigma, Oakville ON, Canada) were used to normalize protein levels. Secondary 
horseradish peroxidase-conjugated antibodies (1:5000) (anti-rabbit IgG A4914, anti-
mouse IgG, A8924, Sigma, Oakville ON, Canada) were incubated for lhr and visualized 
by chemiluminescence (Amersham ECL plus, Baie d'Urfe QC, Canada) using the 
Carestream Software and Kodak Imager (4000MM Pro) (Kodak, Woodbridge CT, USA). 
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Statistical analysis. 
Results are expressed as mean ± standard error of the mean. Analyses were 
performed using paired student's t-test and 1-way ANOVA (significance between two 
groups), or 2-way ANOVAs (significance between groups over time) with Bonferoni 
Post tests using Graphpad Prism 5.0 software (La Jolla CA, USA). Significance was 
declared if p-values were less than 0.05. 
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Figure 2.1 In vivo experimental approach establishing effects of overexpressing dsAAV8-
RIP-eGFP in pancreatic p-cells in mice. Four-month-old male C57B16 mice were 
infected with either dsAAV8-RIP-eGFP (P-eGFP-Control) (5.0xl012 viral 
genomes/mouse) or saline (284|J/mouse). Body weights (weekly), 4hr fasted blood 
glucose readings (biweekly), oral glucose tolerance (end point), and insulin tolerance 
(end point) were assessed. Additionally western blot analysis was utilized to determine if 
eGFP was being expressed in other tissues other than pancreatic P-cells. Abbreviations: 
dsAAV8 - double stranded adeno-associated virus serotype 8; RIP - rat insulin promotor; 
eGFP - enhanced green fluorescent protein. 
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2.3 RESULTS 
Overexpression of dsAAV8-RIP-eGFP is targeted to P-cells and not the a-cells of the 
pancreas. 
Immunohistochemical analysis of pancreas sections collected from dsAAV8-RIP-
eGFP infected mice show eGFP immunofluorescence colocalized with insulin 
immunofluorescence (Fig. 2.2a) as indicated by the green and red overlay; whereas no 
colocalization was observed between eGFP and glucagon immunofluorescence (Fig. 
2.2b). These results are supported by previous studies from Gaddy et al (2010) and Riedel 
et al (2010); further confirming that eGFP protein expression using dsAAV8-RIP-eGFP 
is localized to the P-cell with no expression in the a-cell of the islets or the exocrine 
tissue of the pancreas. As expected, no eGFP expression was observed in pancreatic 
sections collected from saline infected mice. Moreover, eGFP was found to be expressed 
in 60% of the total islet area in eGFP infected islets from an ip injection (Fig 2.2c). 
Pancreatic p-cell specific overexpression of eGFP driven by the rat insulin promoter 
does not cross the blood brain barrier. 
Due to the observation that RIP-Cre transgenic mice have been shown to drive 
recombination of conditional gene knockouts in hypothalamic neurons as well as 
pancreatic p-cells (Choudhury et al. 2005; Choi et al. 2008), we examined if eGFP 
expressed from dsAAV8-RIP-eGFP and delivered by dsAAV8 was expressed in 
hypothalamic neurons of dsAAV-RlP-eGFP infected mice. Western analysis of protein 
extracts from hypothalamic tissue we detected no expression of eGFP suggesting the 
adeno-associated virus did not cross the BBB or the RIP promoter was not active in 
neurons of the hypothalamus in these mice (Fig. 2.3). 
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Figure 2.2 Immunohistochemical analysis to detect eGFP overexpression in pancreatic P-
cells. Overexpression of dsAAV8-RIP-eGFP shows targeted expression of eGFP in P-
cells (A) and not a-cells (B) of the pancreas of C57B16 mice. (C) Percentage of eGFP 
immunoreactive area in total islet area. Abbreviations: dsAAV8 - double stranded adeno-
associated virus serotype 8; RIP - rat insulin promotor; eGFP - enhanced green 
fluorescent protein; INS - insulin; GLC - glucagon . Saline-treated n=7, P-eGFP-Control 
n=7. Images taken at 20x magnification. Scale bar 50p.m. 
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Figure 2.3 Western blot analysis of dsAAV8-RIP-eGFP expression in non-pancreatic 
tissues. Overexpressing dsAAV8-RIP-eGFP in pancreatic p-cells does not cross the BBB 
showing no expression in the hypothalamus. 30]ig of protein per sample was loaded and 
run (see methods); (3-Actin was utilized as a protein control. Abbreviations: dsAAV8 -
double stranded adeno-associated virus serotype 8; RIP - rat insulin promotor; eGFP -
enhanced green fluorescent protein; NT - non-transfected MIN6 cells; (-) negative 
control; eGFPM - eGFP transfected MIN6 cells; (+) positive control. 
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Overexpression of dsAAV8-RIP-eGFP is not expressed in skeletal muscle or liver. 
We examined expression of eGFP in peripheral tissues (liver, intestine and 
skeletal muscle) of mice that received virus carrying dsAAV8-RIP-eGFP and saline 
control mice, using western blot analysis. No eGFP expression was observed in skeletal 
muscle or intestine protein extracts in both dsAAV8-RIP-eGFP expressing mice and 
saline control mice. Non-specific bands were observed in skeletal muscle and liver 
protein extracts of both |3-eGFP-control and saline mice (Fig. 2.4). It should be noted that 
the increased brightness observed in liver protein extracts raised concern and required 
further investigation as dsAAV8 has been reported to target liver and skeletal muscle 
tissue in addition to the pancreas (Chao et al. 2000; Gao et al. 2002; Wang et al. 2004; 
Wu et al. 2006); therefore we had to confirm if the non-specific bands were real. 
To do this, we decided to perform immunohistochemical analysis using the same 
antibodies utilized of the western blot. Skeletal muscle and liver tissue samples of both 
P-eGFP-control and saline mice were sectioned and stained for eGFP using 
immunohistochemistry. It was observed that eGFP was not expressed in either skeletal 
muscle or liver tissue (Fig. 2.5a) in both P-eGFP-control and saline mice. Intensity of 
eGFP observed was identical to the background staining in the no primary (1°) antibody 
control. As an additional control for immune reactivity, pancreatic sections (Fig. 2.5b) 
were stained for eGFP and insulin. This allowed us to confirm that under the same 
conditions and concentrations the antibody to eGFP and blocking solutions utilized for 
immunohistochemical analysis was able to detect eGFP in pancreatic P-cells as 
previously shown. 
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Figure 2.4 Western blot analysis of dsAAV8-RJP-eGFP expression in non-pancreatic 
tissues. Overexpressing dsAAV8-RIP-eGFP in pancreatic P-cells does not target skeletal 
muscle or intestine. Non-specific binding of eGFP was observed in liver tissue in both 
dsAAV8-RIP-eGFP mice and saline controls. 30(ig of protein per sample was loaded and 
run (see methods); P-Actin was utilized as a protein control. Abbreviations: dsAAV8 -
double stranded adeno-associated virus serotype 8; RIP - rat insulin promotor; eGFP -
enhanced green fluorescent protein; NT - non-transfected MIN6 cells; (-) negative 
control; eGFPM - eGFP transfected MIN6 cells; (+) positive control; SKM - skeletal 
muscle. 
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Figure 2.5 Immunohistoehemical analysis of dsAAV8-RIP-eGFP overexpression in non­
pancreatic tissues. Staining revealed no eGFP expression in liver (A) or skeletal muscle 
(B) tissues above background staining (secondary antibody AF488 only) in p-eGFP-
Control mice when compared to saline controls. Pancreas sections (C) were stained as 
positive controls to show level of eGFP expression when cells are overexpressing eGFP. 
Abbreviations: dsAAV8 - double stranded adeno-associated virus serotype 8; RIP - rat 
insulin promotor; eGFP - enhanced green fluorescent protein; 10 - primary; CNTRL -
control. Images taken at 20x magnification. Scale bar 50|xm. 
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Pancreatic p-cell specific overexpression of eGFP using dsAAV8-RIP in mice does 
not affect carbohydrate metabolism. 
We utilized a RIP driven expression vector delivered by dsAAV8 to generate 
mice overexpressing eGFP specifically in pancreatic P-cells. We confirmed that control 
mice expressed eGFP specifically in pancreatic P-cells (dsAAV8-RIP-eGFP) with no 
effect on body weight, 4 hr fasted blood glucose levels, oral glucose tolerance or insulin 
sensitivity when compared to control mice injected with saline (Fig. 2.6 a-d). These 
results, and similar results from others (Gaddy et al. 2010) confirm dsAAV8-RIP-eGFP is 
an appropriate control virus for in vivo overexpression studies using dsAAV8. 
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Figure 2.6 Body weight and carbohydrate metabolism from 3wk post-infection with 
dsAAV8-RIP-eGFP (P-eGFP-Control) or saline (284|^l/mouse) by ip injection. 
Overexpression of eGFP in pancreatic P-cells resulted in no change in body weight (A), 
4hr FBG (B), glucose tolerance (C, 2g D-glucose/kg), or insulin sensitivity (D, 0.75U 
insulin/kg) compared to saline-treated mice on regular chow diet. Abbreviations: 
dsAAV8 - double stranded adeno-associated virus serotype 8; RIP - rat insulin promotor; 
eGFP - enhanced green fluorescent protein; FBG - fasted blood glucose. Saline-treated 
n=7, P-eGFP-Control n=7. Mean values +/- standard error of the mean are shown. 
Statistical significace was tested by 2-way ANOVA (over time) with Bonferoni Post 
Tests or Student's t-Tests (at specific time points). 
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2.4 DISCUSSION 
Transgenic mice driven by the RIP start expressing the gene or protein of interest 
as early as embryonic day 13.5 (Hara et al. 2003); thus, showing overxpression of the 
gene of interest before birth, from El 3.5. In addition, when utilizing RIP-Cre 
transgenics, there is a possibility that the protein of interest will also be expressed in the 
hypothalamic neurons of the brain (Choudhury et al. 2005; Choi et al. 2008; Dahlhoff et 
al. 2011). It has been described previously, that as little as a 10% reduction in body 
weight can have significant improvements in whole body carbohydrate metabolism 
(Smyth and Heron 2006). Since the hypothalamus is responsible for appetite regulation 
(Inui 1999), overexpression of proteins in the hypothalamus by RIP can impact 
carbohydrate metabolism and p-cell function. Choi and colleagues (2008) speculated that 
manipulating hypothalamic neuronal activity by overexpressing Cre and increased 
protein production can regulate whole body growth (Choi et al. 2008) as seen in their 
RIP-Cre mouse. These characteristics of RIP transgenics were considered when deciding 
on the most appropriate method for implementing P-cell specific overexpression of 
PPARa and assessing its effects on p~cell lipotoxicity in a diet-induced obese model of p-
cell failure and T2D. If we were to use a RIP-PPARa transgenic mouse overxpressing 
PPARa, we would induce PPARa expression from El3.5 in the developing pancreas as 
well as the potential expression in the adult hypothalamus. Thus, we would not be able to 
easily discern if the physiological results obtained are solely from pancreatic p-cell 
overexpression of PPARa or additionally related to these cofounding expression patterns. 
Therefore methods of inducible overexpression seem more favorable when characterizing 
genes of interest in an in vivo model. 
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Recently, a new gene delivery tool has been developed for targeted delivery of 
proteins to p-cells of the pancreas via intraperitoneal injection utilizing dsAAV8 vectors 
(Wang et al. 2006; Gaddy et al. 2010; Riedel et al. 2010) under the direction of the rat-
insulin promoter. Here we demonstrate that viral delivery of dsAAV8-RIP-eGFP is 
specifically targeted to pancreatic P-cells and not a-cells (Fig. 2.2 a, b) or exocrine tissue 
of pancreas. Overall these results indicate that the delivery of dsAAV8-RIP-eGFP via 
intraperitoneal injection prove to be an effective, non-invasive method of viral gene 
transfer for targeted protein delivery to the p-cells of the pancreas. 
By overexpressing eGFP in the P-cells of the pancreas, we are forcing the P-cell 
to increase the production of foreign proteins. This increased protein production could 
potentially lead to decreased insulin secretion and the development of P-cell dysfunction 
or P-cell exhaustion. Therefore it was crucial to determine if expressing foreign proteins 
would affect the overall health of the P-cell. We determined that overexpression of 
dsAAV8-RIP-eGFP in the pancreatic p-cells did not affect body weight or overall 
carbohydrate metabolism (Fig. 2.6), further proving to be a useful control vector for 
future in vivo studies involving diabetic models. 
Importantly, we have also confirmed that dsAAV8-RIP-eGFP does not cross the 
BBB (Fig. 2.4) similar to the results obtained by Wang and colleagues (2006), thus 
avoiding gene expression in hypothalamic neurons that may cause changes in appetite 
regulation controlled by the hypothalamus (Devaskar et al. 1994; Gannon et al. 2000). 
eGFP has been shown to be expressed in liver and skeletal muscle (Inagaki et al. 2006; 
Wu et al. 2006) when using dsAAV8. During western blot analysis non-specific bands 
were observed in both skeletal muscle and liver protein extracts (Fig. 2.4) from P-eGFP-
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control and saline mice. However, after close observation the bands observed were not 
detected at 27kDa (eGFP positive control) they were found to have a slightly higher 
molecular weight as seen in the shift on the membrane. It should be noted that protein 
extracts from liver in P-eGFP-control mice were found to have bands of increased 
intensity around 27kDa, indicating that eGFP may be expressed in these tissues; thus 
immunohistochemical analysis was also performed. Moreover, our group concluded that 
these bands were indeed non-specific based on the observation that chemiluminescence 
was detected in protein extracts of saline injected mice in both liver and skeletal muscle. 
Due to these unexpected results from western blot analysis, our group has 
confirmed that eGFP is not expressed in skeletal muscle or liver tissue of P-eGFP-control 
mice, using immunohistochemical analysis of paraffin embedded sections, that no eGFP 
staining was observed above background fluorescence (Fig 2.5a, b). To show positive 
staining of eGFP, pancreatic tissue sections were stained and used as a positive control 
for "real" eGFP staining (Fig. 2.5c). One may argue that there are intensely stained areas 
of green in the liver section of P-eGFP-control mice, however these intense patches of 
green were also observed in saline islets (Fig. 2.5c middle panel) indicating that these 
could be autofluorescing red blood cells, increased background staining, or non-specific 
staining observed in western results. 
Based on our results and those obtained by our colleagues (Gaddy et al. 2010; 
Riedel et al. 2010), it should be noted that utilizing dsAAV8 for P-cell specific gene 
delivery is an appropriate vector for developing and characterizing in vivo models of p-
cell overexpression. In addition we have been able to show effective gene delivery (Fig. 
2.2a, b) to the target tissue (P-cells) through a non-invasive interperitoneal injection. 
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Furthermore, we have shown eGFP expression to be observed in 60% of total islet area of 
infected islets (Fig 2.2c). Importantly, the use of an ip injection opposed to intraductal 
injections allows user groups to avoid complications associated with invasive surgery 
such as recovery time, weight loss and potential death. Having shown the same 
efficiency of viral delivery as our colleagues (Wang et al. 2006; Riedel et al. 2010), 
utilizing the interperitoneal injection for our future studies will prove to be critical, as we 
want to ensure that any changes observed in our model is due solely to the 
overexpression of PPARs in the p-cells, and not due to weight loss caused by the invasive 
surgery of performing intraductal injections. 
It has been proposed by Wang et al (2006), Gaddy et al (2010) and Riedel et al 
(2010) that there is the potential of utilizing dsAAV8 as a potential therapeutic for 
targeted pharmaceuticals or as a method of targeted gene therapy in diabetic individuals 
(Gaddy et al. 2010; Riedel et al. 2010). Again, the use of dsAAV8 under the control of 
RIP is also attractive as it specifically targets the pancreatic p-cells, therefore if it were to 
be used as a method of gene therapy in diabetes treatments, we could potentially avoid 
systemic complications as seen with some pharmaceuticals. As previously discussed, 
Gaddy et al. (2011) and Montane et al. (2011) have both utilized dsAAV8 mediated gene 
delivery to either reverse hyperglycemia or protect against further autoimmune 
destruction of P-cells in T1D mice (Gaddy et al. 2011; Montane et al. 2011). Moreover, 
improvements were seen after a single ip or intraductal injection (Gaddy et al. 2011; 
Montane et al. 2011). These studies have shown that dsAAV8 could be a potential 
therapeutic for the treatment of T1D, thus making it especially appealing to current 
patients, as well as parents of T1D kids as an alternative to islet transplantation. 
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The results obtained in this study were similar to those obtained by Gaddy et al 
(2010) and Riedel et al (2010); further proving to be an effective tool in in vivo diabetic 
models opposed to traditional models of transgenics. The major findings from this 
chapter are: 
1. dsAAV8 is an effective tool for gene delivery to the pancreatic P-cells. 
2. Overexpression of dsAAV8-RIP-eGFP is observed in p-cells and not a-cells 
of the pancreas as early as three weeks post infection. 
3. Overexpression of dsAAV8-RIP-eGFP is not expressed in the hypothalamus 
of the brain, or peripheral tissues (skeletal muscle, liver and intestine). 
4. Overexpression of dsAAV8-RIP-eGFP within the pancreatic p-cells does not 
affect body weight or carbohydrate metabolism. 
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CHAPTER 3 
Overexpression of PPARa in the Pancreatic p-cells Improves Carbohydrate 
Metabolism in a Model of Diet-induced Obesity 
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improves glucose tolerance in diet-induced obese mice. Canadian Journal of Diabetes. 
35(4): 417. Canadian Diabetes Association AGM & Professional Meetings. Toronto ON. 
Oct 26-29 2011. 
A version of this chapter has been submitted: 
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Gray, Sarah L. 2012. Overexpression of PPARa in pancreatic P-cells improves glucose 
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3.1 INTRODUCTION 
As previously outlined in chapter one, lipotoxicity is implicated as a mechanism 
in p-cell dysfunction and development of obesity-induced T2D in (Virtue and Vidal-Puig 
2010). Therefore protecting the pancreatic P-cells from increased lipid accumulation may 
be a plausible approach to reducing lipotoxicity and preserving P-cell function. 
The peroxisome proliferator-activated receptors (PPARs) are nuclear transcription 
factors involved in the regulation of lipid metabolism (Chinetti et al. 2000). PPARa is 
often expressed in tissues including the liver, skeletal muscle, heart and pancreas (Lee et 
al. 2003). Activation of PPARa upregulates expression of p-oxidative genes (Tordjman 
et al. 2002; Lalloyer et al. 2006; Medina-Gomez et al. 2007) with subsequent 
improvements in glucose homeostasis by decreasing circulating lipids and lipid 
accumulation in non-adipose tissues such as liver and skeletal muscle, consequently 
reducing lipotoxicity and increasing insulin sensitivity (Sugden et al. 2003; Lalloyer et al. 
2006). Figure 3.1 illustrates the binding of PPARa to RXR where it forms a heterodimer 
prior to nuclear internalization. Once in the nucleus, the PPARa/RXR heterodimer binds 
to the PPAR response element (PPRE) where gene transcription remains inactive until the 
activating ligand (FA or FA derivatives, or PPAR agonist) binds to PPARa/RXR, causing 
the release of the corepressor complex (CRC) and histone deacetylases (HDACs) and 
subsequent binding of the coactivator complex (CAC) which recruits histone 
acetyltransferases (HATs). The PPARa/RXR/CAC complex is then active and the 
transcription of downstream target genes can occur, including the transcription of genes 
involved in fatty acid metabolism and p-oxidation (Reddy and Hashimoto 2001; Mandard 
et al. 2004). 
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Figure 3.1 - Regulation of gene expression by PPARs (Binding of PPAR/Retinoid 
Nuclear Receptor Family) modified from (Reddy and Hashimoto 2001). The PPAR/RXR 
family is involved in controlling gene transcription at the nuclear level. Abbreviations: 
FA - fatty acid; PPAR - peroxisome proliferator-activated receptor; Pa - PPARa; RXR -
retinoid-X receptor; CRC - corepressor complex; HDACs - histone deacetylases; PPRE 
- PPAR response element; CAC - coActivator complex; HATs - histone 
acetyltransferases. 
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When PPARa is activated, numerous downstream target genes involved in (3-
oxidation and lipid metabolism are turned on (Mandard et al. 2004). Some of the genes 
upregulated by PPARa include: Acyl-CoA oxidase (AOX), carnitine palmitoyl 
transferase-1 (CPT1), long chain acyl-coA dehydrogenase (LCAD), and uncoupling 
protein-2 (UCP2) (Reddy and Hashimoto 2001; Lee et al. 2003). Expression of these 
target genes varies depending on tissue selected (Mandard et al. 2004). Increased 
expression and PPARa activation occurs largely in the liver (Lee et al. 2003), where a 
decrease in triglyceride synthesis and increased oxidation of fatty acids is observed 
(Frederiksen et al. 2004). It should be noted that previous studies have reported that 
prolonged exposure to increased PPARa activity in the liver has been linked to 
heptacellular carcinoma in rats and mice (Qin et al. 1997; Gonzalez et al. 1998; Reddy 
and Hashimoto 2001). In contrast, PPARs have been found to be nonmutagenic in nature 
after increasing metabolic activity (Gonzalez et al. 1998; Reddy and Hashimoto 2001); 
therefore proving to be a potential tool in tissue-specific gene manipulation in in vivo 
studies. 
Studies utilizing PPARa null mice or systemic administration of PPARa agonists 
have contributed greatly to elucidating the physiological role of PPARa. Loss-of-function 
studies have shown that animals lacking PPARa are protected against high-fat diet 
induced obesity and insulin resistance (Guerre-Millo et al. 2001); where PPARa was 
found to be non-essential for the maintenance of euglycemia, but required to maintain the 
P-cell adaptive response to hyperglycemia (Guerre-Millo et al. 2001; Bihan et al. 2005; 
Yessoufou et al. 2009). Moreover, Lalloyer and colleagues (2006) utilized PPARa-null 
ob/ob mice to show that PPARa deficiency in a severely obese model (ob/ob) resulted in 
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increased P-cell dysfunction with reduced islet area and decreased glucose-stimulated 
insulin secretion (Lalloyer et al. 2006). It should also be noted that PPARa-null mice 
often suffer from hypoglycemia under prolonged fasting (Guerre-Millo et al. 2001; 
Lalloyer et al. 2006). This hypoglycemia is believed to be attributed to depleted 
glycogen stores in PPARa-null mice, (Kersten et al. 1999; Lee et al. 2003; Mandard et al. 
2004) 
Gain of function studies utilizing systemic administration of PPARa agonists in 
OLETF rats, prevented FFA-induced P-cell dysfunction (Koh et al. 2003; Lalloyer et al. 
2006). PPARa agonists have been shown to improve hepatic insulin sensitivity by 
enhancing hepatic expression of p-oxidative genes (Bergeron et al. 2006), strongly 
supporting the notion that PPARa agonists decrease lipid accumulation in peripheral 
tissues such as liver (Holness et al. 2003; Koh et al. 2003; Bergeron et al. 2006). 
Additionally, Yajima and colleagues (2003) have shown that administrating a 
combination of PPARa and PPARy agonists increased glucose-stimulated insulin 
secretion by increasing insulin stores in P-cells of db/db mice (Yajima et al. 2003). 
Because the above studies report the effects of systemic PPARa deletion or agonism, the 
direct effect of PPARa on pancreatic P-cell function cannot conclusively be determined 
as direct or secondary and thus it remains unclear if the beneficial effects of PPARa on P-
cell function are due to reductions in circulating lipid levels via actions on the liver, or 
direct effects on the p-cell itself. 
Studies utilizing both isolated islets and P-cell lines have provided evidence that 
PPARa activation is able to improve p-cell function directly. Hellemans et al (2007) 
showed that in isolated rat islets, activation of PPARa protected against palmitate-
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induced toxicity through increased mitochondrial and peroxisomal P-oxidation 
(Hellemans et al. 2007). More recently, Frigerio and colleagues (2010) utilized 
adenoviruses to overexpress PPARa and retinoid X receptor (RXR) in the INS-IE p-cell 
line (Frigerio et al. 2010). Overexpressing PPARa in this clonal cell line resulted in 
restored glucose-stimulated insulin secretion in oleate-treated cells by promoting glucose 
metabolism and fatty acid storage (Frigerio et al. 2010). Frigerio et al (2010) proposed 
that overexpression of PPARa in the INS-IE cells increased fatty acid turnover through 
consumption via p-oxidation; it was also proposed that the protective effects observed 
with PPARa overexpression could be due to increased triglyceride synthesis (Frigerio et 
al. 2010). Further supporting the protective effects of PPARa, Lalloyer et al (2007) were 
able to show that treatment with PPARa agonists under lipotoxic conditions improved 
insulin secretion in isolated human islets (Lalloyer et al. 2006). These improvements 
were associated with decreased islet triglyceride content and decreased palmitate-induced 
apoptosis (Lalloyer et al. 2006). Together, these studies provide evidence that activation 
of PPARa in isolated islets and p-cell lines may protect against lipotoxic induced P-cell 
dysfunction through the regulation of lipid metabolism in islets. 
Based on the above in vivo and in vitro studies showing favorable effects of 
PPARa agonism on p-cell function in the context of lipid exposure and high-fat feeding, 
we hypothesized that overexpression of PPARa specifically in pancreatic P-cells of obese 
mice, in vivo, would preserve pancreatic P-cell function and delay the onset of obesity-
induced diabetes. 
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3.2 MATERIALS AND METHODS 
Cell Culture. 
There are several p-cell lines currently utilized to study the in vitro effects of 
lipotoxicity on the P-cell and its role in the pathogenesis of T2D. When available, 
isolated islets are preferred; however islets are difficult to isolate, and can become 
expensive to obtain, as whole mice must be sacrificed for the collection of islets. In 
addition to primary islets, insulinoma cell lines are commercially available for in vitro 
studies looking at p-cell function. Of the P-cell lines, the MIN6 and INS-IE cells are 
often most utilized for their P-cell characteristics (Xiao et al. 2001; Tordjman et al. 2002; 
Ravnskjaer et al. 2005; Frigerio et al. 2010). The use of these cell lines will depend on 
what tests, and data one wants to collect. INS-IE cells have been found to be more easily 
cultured, however they have less regulation of insulin secretion and higher basal insulin 
levels without a stimulus (Skelin et al. 2010). Whereas the MIN6 cells, act and respond 
more like P-cells, in a glucose dependent manner; where insulin is secreted appropriately 
in response to a glucose stimulus (Skelin et al. 2010). 
MIN6 cells (passage 15- 25) were cultured at 37°C and 5% CO2 in media 
containing Dulbecco's Modified Eagle's Media (DMEM) (D5671, Sigma, Oakville ON, 
Canada), 200mM L-glutamine, 50jjmol/L P-mercaptoethanol, 10% FBS (vol/vol), and 
100 U/ml penicillin-streptomycin). Cells were transfected at 80-90% confluencey as 
previously described (Dalby et al. 2004) using lipofectamine 2000 (lfil) (Invitrogen, 
Burlington ON, Canada) and 1.6(ig of plasmid (plasmid dsAAV8-RIP-eGFP or plasmid 
dsAAV8-RIP-PPARa) (Fig. 3.2). Enhanced green fluorescent protein (eGFP) was 
visualized by fluorescent microscopy to assess transfection efficiency 24hrs post 
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transfection; experiments that produced 60% or more eGFP expressing cells were 
considered to be successfully transfected. For experiments requiring palmitate treatment, 
cells were exposed to the above culture media containing OjxM or 250[iM BSA-coupled 
palmitate (6:1) (Gwiazda et al. 2009) for 48hrs one day post-transfection. 20mM stock 
palmitic acid was prepared daily as follows: 5.6mg of palmitic acid was dissolved in 1ml 
of H2O containing l(il ofNaOH at 70°C; once dissolved 0.5ml of 20mM palmitic acid 
was added to 1.65ml of 20% FA free BSA, and added to 17.85ml of cell culture media 
for a final stock concentration of 500^M. Stock palmitate solutions were then diluted to 
working concentrations of 250fiM prior to treating cells. 
RNA extraction and cDNA generation. 
RNA was extracted (RNeasy kit, Qiagen, Valencia CA, USA) from cells 24 hrs 
post transfection. Genomic DNA was removed from RNA extracts using lOx TURBO 
DNAse buffer (5|il) and TURBO DNAse (1 jal) and incubated at 37°C for 1 hr as per the 
manufacturers protcol (TURBO DNAse Kit, Ambion, Burlington ON, Canada). RNA 
concentration and purity were assessed by spectrophotometry (nanodrop 
spectrophotometer, ND-1000, Thermo Scientific, Rockford IL, USA) and RNA integrity 
was assessed by visualizing intact 18s and 28s rRNA bands on a 1.5% agarose gel. Intact 
RNA (500ng) was reverse transcribed to cDNA using random primers (5jj.1), dNTPs 
(1 (.il), dH^O (jc-jj-1 to total volume of 13^1) and incubated at 65°C for 5min, then first 
strand buffer (4|il), 0.1M DTT (1 j_il) and superscriptlll (1 jj.1) added to each reaction and 
incubated in the thermocycler as per the manufacturers protocol (Superscript III Reverse 
Transcriptase kit, Invitrogen, Burlington ON, Canada). 
Quantitative Real-time PCR. 
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PPARa mRNA expression levels in MIN6 cells and induction of PPARa target 
gene mRNA expression were assessed using quantitative real-time PCR normalized to 
the reference genes p-Actin and 18s. Taqman primer and probe sequences for PPARa, 
carnitine palmitoyl transferase-1 (CPT1), long-chain acyl-CoA dehydrogenase (LCAD), 
Acyl-CoA oxidase (AOX), uncoupling protein-2 (UCP2), P-actin and 18s are shown in 
Table 1 (Sigma,) and qPCR master mix contained: iQ Supermix, Taqman forward and 
reverse primers (5|iM), Taqman probes (5JJM), RNAse free H2O, cDNA (lfil) (BioRad 
Laboratories, Hercules CA, USA; Sigma, Oakville ON, Canada; Ambion, Austin TX, 
USA). The following reaction conditions were used for each RT-PCR: one cycle of 50°C 
for 2min, 95°C for lOmin followed by 40 cycles of 95°C for 15sec, 60°C for lmin 
(BioRad iQ5 Multicolor RT-PCR Detection System, BioRad Laboratories, Hercules CA, 
USA). All qRT-PCR reactions followed the MIQE guidelines (Bustin et al. 2009) where: 
1) Each biological replicate (experimental and control) was completed in 
triplicate 
2) RNA extracts were treated with DNAse to remove genomic DNA 
3) RNA quality was assessed using slab gel electrophoresis 
4) cDNA was prepared immediately after RNA quality assessment 
5) Primers and probes were previously designed by groups using qRT-PCR 
6) R2 values were 0.980 or greater, with efficiencies between 90-115% 
7) Several reference genes (18S and p-Actin) were used for normalization 
8) Each biological replicated was run as a technical triplicate for maximum 
reproducibility. 
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Table 3.1 Taqman primer and probe sequences used to assess mRNA expression levels of 
PPARa and PPARa target genes using quantitative PCR. 
Gene Forward Primer (5'-3') Reverse Primer (5'-3') Probe (5'-3') 
PPARa CCTCAGGGTACCACTACGGAGT GCCGAATAGTTCGCCGAAA CACGCATGTGAAGGCTGTAAGGGCTT 
CPT1 GCGTGCCAGCCACAATTC TCCATGCGGTAATATGCTTCAT CCGGTACTTGGATTCTGTGCGGCC 
LCAD GCATGAAACCAAACGTCTGGA TGTTTTGTAATTCAGATGCCCAGT TCCGGTTCTGCTTCCATGGCAAAA 
AOX AATTGGCACCTACGCCCAG AGTGGTTTCCAAGCCTCGAA CGGAGATGGGCCACGGAACTCA 
UCP2 GATCTCATCACTTTCCCTCTGGATA CCCTTGACTCTCCCCTTGG CGCCAAGGTCCGGCTGCAGA 
(3-Actin GCTCTGGCTCCTAGCACCAT GCCACCGATCCACACAGAGT GATCAAGATCATGCTCCTCCTGAGCGC 
18S CGGCTACCACATCCAAGGAA GTCGGAATTAC CGCGGCT GAGGGCAAGTCTGGTGCCAG 
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Glucose-stimulated insulin secretion. 
MIN6 cells were cultured and transfected with respective plasmids (plasmid 
dsAAV8-RIP-eGFP and plasmid dsAAV8-RIP-PPARa) and treated with either 0|iM or 
250|iM BSA coupled-palmitate for 48 hrs as described above. Cells were incubated for 
lhr in glucose-free KRH Buffer (5M NaCl, 1M KC1, 1M Mg2S04, 1M NaHCCh, 1M 
CaCl2, 0.5M KH2P04, 1M HEPES, 0.5g BSA) (Sigma, Oakville ON, Canada), before 
being exposed to basal (2.8mmol/l) and stimulating (20mmol/l) levels of D-glucose for 1 
hour each (Frigerio et al. 2010). After each incubation, 1ml of media was collected and 
insulin levels quantified. 5^1 of each sample was run in triplicate with conjugate buffer 
(75|il) and shaken at 800rpm on a microplate shaker for 2 hrs at room temperature. 
Samples were then washed with wash buffer and incubated for 15min at 800rpm with 
TMB substrate. Stop solution was then added to samples and quantified at 450nm on a 
plate reader (Ultrasensitive insulin ELISA assay, 80-INSMSU-E10, ALPCO, Salem NH, 
USA). Protein was extracted using 100(j.l RIPA buffer/well per 24-well plate (lOpl 
HALT buffer and 10|il EDTA per 1ml RIPA) (Thermo Scientific, Rockford IL, USA) 
and quantified in using a bicinchoninic acid (BCA) assay. 25^1 of each sample was run 
in triplicate with 200^1 of working reagent and incubated at 37°C for 30min. Plates were 
cooled to room temperature prior to quantifying at 560nm on a plate reader (Thermo 
Scientific, Rockford IL, USA). Secreted insulin levels (ng/ml) were normalized to total 
cellular protein (mg/ml) per well (ng/ml/mg protein). 
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Figure 3.2 In vitro experimental approach utilized in the expression of PPARa in MIN6 
cells (in vitro). Abbreviations: PPARa - peroxisome proliferator-activated receptor 
alpha; MIN6 - mouse insulinoma cell line; BSA - bovine serum albumin; GSIS -
glucose-stimulated insulin secretion. 
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Mice. 
AH animal studies were approved by the University of Northern British Columbia 
Animal Care and Use Committee (protocol number 2011-21). For all experiments, 6-
week-old, male, C57B16 mice were purchased from Charles River Laboratories 
(Wilmington MA, USA) unless otherwise stated. Mice were maintained on a 12 hr 
light/dark cycle and received standard rodent chow diet (Rodent LabDiet, 5001, Leduc 
AB, Canada) ad libitum unless otherwise stated. Mice were allowed to acclimatize to the 
animal facility for 1 week prior to performing any experimental procedures. Body weight, 
4 hr fasted blood glucose (OneTouch Ultra, Lifescan, Burnaby BC, Canada), oral glucose 
tolerance tests (OGTT) and insulin tolerance tests (ITT) were performed prior to viral 
injections to assess baseline carbohydrate metabolism. 
Double-stranded adeno-associated virus serotype 8. 
dsAAV8 transfer vectors were designed utilizing the rat insulin 1 promoter (RIP) 
(410 bp) placed upstream of either a sequence encoding eGFP (720bp) or the mouse 
PPARa (1407bp) open reading frame, followed by the SV40 polyadenylation signal. 
Complete dsAAV8-RIP-eGFP (5328bp) and dsAAV8-RIP-PPARa (6015bp) vectors 
were sent to Children's Hospital Of Philadelphia (CHOP) Research Vector Core Services 
(Philadelphia PA, USA) for AAV8 virus preparation 
Pancreatic P-cell specific overexpression of PPARa in high fat diet-induced obese 
mice. 
At 4-months old, C57B16 mice were infected with dsAAV8-RIP-PPARa virus (P-
PPARa-HFD, n=8; 5xl012 viral genomes/814.3}il/mouse) or dsAAV8-RIP-eGFP virus 
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(P-eGFP-HFD control group, n=6; 5xl012 viral genomes/552.5|il/mouse) via ip injection. 
Body weights were monitored weekly; 4 hr fasted blood glucose was monitored biweekly 
and glucose tolerance and insulin sensitivity were assessed monthly by OGTT and ITT 
respectively. Two days post injection mice were switched to a high fat diet containing 
45% kcal as fat (D12451, Research Diets, New Brunswick NJ, USA) ad libitum 
throughout the remainder of the experiment (20 weeks) when all animals were sacrificed 
(Fig. 3.3). Tissues were collected and flash frozen or fixed in 4% paraformaldehyde for 
48hrs and then stored in 70% EtOH. Whole pancreas sections were prepared by WAX-
IT histological services (Vancouver BC, Canada). 
Insulin tolerance tests. 
Mice were fasted for 4 hrs and given an ip injection of human synthetic insulin at 
0.75U/kg or l.OU/kg (Novolin Ge, Toronto ON, Canada). Blood was sampled (l-2jxl) 
from the saphenous vein and blood glucose measured (mmol/L) at 10, 20 30, 60, and 120 
min post injection using handheld glucometer (OneTouch Ultra, Lifescan, Burnaby BC, 
Canada). 
Oral glucose tolerance and glucose-stimulated insulin secretion. 
Mice were fasted for 16 hrs and given 2g/kg D-glucose by oral gavage. Plasma 
(15-20|xl) was sampled for insulin measurement at 5, 10 and 180 minutes post glucose 
gavage from the saphenous vein and blood glucose (mmol/L) measured in 1 -2|il blood at 
5, 10, 30, 60, 120 and 180 minutes post gavage using handheld glucometer (OneTouch 
Ultra, Lifescan, Burnaby BC, Canada) (Huynh et al. 2010). 
Overnight fasted and re-fed plasma insulin levels. 
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Mice were fasted for 16 hrs and blood collected in heparinized capillary tubes 
(Fisher Scientific, Ottawa ON, Canada) from the saphenous vein. Food was reintroduced 
for 2 hrs and plasma collected again. Blood glucose was determined using a handheld 
glucometer (OneTouch Ultra, Lifescan, Burnaby BC, Canada) and plasma insulin levels 
were assessed by ELISA (Ultrasensitive insulin ELISA assay, 80-INSMSU-E10, 
ALPCO, Salem NH, USA). 
Immunohistological analysis. 
Whole mouse pancreas sections fixed in 4% paraformaldehyde and embedded in 
paraffin were sectioned at 5^m thickness; n=5 per group (Wax-it Histology Services; 
Vancouver BC, Canada). All sections were de-paraffinized and rehydrated as described 
previously in chapter 2 (Riedel et al. 2010). Sections were incubated with polyclonal 
primary antibodies to rabbit anti-eGFP (1:500) (Al 1122, Invitrogen Molecular Probes, 
Carlsbad CA, USA), polyclonal guinea pig anti-insulin (1:1000) (4011-01F, Millipore, 
Billerica MA, USA) and a monoclonal primary antibody to mouse anti-glucagon (1:1000) 
(G2654, Sigma) overnight. Appropriate secondary whole (heavy and light chain) 
antibodies conjugated to Alexafluor 488 (A21206 or A21202) or 594 (A 11076 or 
Al 1032) (1:1000) (Invitrogen Molecular Probes) were used to detect primary antibody 
immunoreactivity. All samples were visualized using a fluorescent light microscope 
(Olympus BX61) and images analyzed using Cell Sens Software (Olympus, Markham 
ON, Canada). 
p-cell mass measurements. 
Insulin immunoreactive-positive area was measured in serial sections of the whole 
pancreas (2 serial sections, 200^m apart from the A. head, B. middle and C. tail of the 
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pancreas (total 3 sections/mouse, n= 4 per group)). Images were captured using the 
ImageXpress® Micro Imaging System and analyzed using MetaXpress® Software 
(Molecular Devices Corporation, Sunnyvale, CA, USA). Total insulin-positive area/total 
pancreas area was multiplied by weight of the whole pancreas (mg) to determine P-cell 
mass (Huynh et al. 2010). 
Statistical analysis. 
Results are expressed as mean ± standard error of the mean. Analyses were 
performed using paired student's t-test and 1-way ANOVA (significance between two 
groups), or 2-way ANOVAs (significance between groups over time) with Bonferoni 
Post tests using Graphpad Prism 5.0 software (La Jolla CA, USA). Significance was 
declared if p-values were less than 0.05. *P<0.05, **P<0.01, ***P<0.001. 
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Figure 3.3 In vivo experimental approach characterizing the physiological effects of 
overexpressing PPARa in the pancreatic p-cells of C57B16 mice in vivo. Four month old 
male C57B16 mice were infected with either dsAAV8-RIP-eGFP ((3-eGFP-HFD) or 
dsAAV8-RIP-PPARa and placed on high-fat diet for 16 weeks. Abbreviations: dsAAV8 
- double stranded adeno-associated virus serotype 8; RIP - rat insulin promotor; eGFP -
enhanced green fluorescent protein; PPARa - peroxisome proliferator-activated receptor 
alpha; FBG - fasted blood glucose; HFD - high-fat diet; ip - intraperitoneal. 
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3.3 RESULTS 
Overexpression of pro-oxidative PPARa in MIN6 cells at a physiological level. 
MIN6 cells successfully transfected with dsAAV8-RJP-PPARa plasmid showed a 
253 + 28 fold increase in PPARa mRNA expression compared to control cells 
overexpressing dsAAV8-RIP-eGFP plasmid (1.0 ± 0.05) (Fig. 3.4a). The level of 
overexpression in MIN6 cells using plasmid dsAAV8-RIP-PPARa was compared to 
PPARa mRNA expression levels observed in fasted liver tissue. Comparison allowed us 
to determine that the levels of PPARa mRNA overexpression achieved in MIN6 cells 
with the above expression vector were within a physiological range, comparable to levels 
observed in fasted liver. 
Overexpression of pro-oxidative PPARa in MIN6 cells results in upregulation of the 
PPARa target gene CPT-1. 
In cells overexpressing PPARa mRNA and exposed to palmitate (250|iM) we 
detected upregulation of one of the four PPARa target genes measured (CPT1, LCAD, 
AOX, and UCP2) (Fig. 3.4b). The 2-fold increase in CPT1 expression that we observed 
has been observed previously in cell models of increased PPARa activity (Xiao et al. 
2001; Ravnskjaer et al. 2005; Hellemans et al. 2007; Frigerio et al. 2010). No significant 
increase in LCAD, AOX or UCP2 was observed in cells overexpressing PPARa with 
palmitate treatment. 
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Figure 3.4 Overexpression of PPARa in MIN6 cells. Overexpression of PPARa in MIN6 
cells occurs at physiological levels (A) and upregulates expression of CPT1 with 
palmitate treatment (B). Overexpressing PPARa in MIN6 cells did not change insulin 
secretion when stimulated with high levels of glucose without palmitate (C). 
Abbreviations: PPARa - peroxisome proliferator-activated receptor alpha; MIN6 -
mouse insulinoma cell line; eGFP - enhanced green fluorescent protein; CPT1 - carnitine 
palmitoyl transferase-1; LCAD - long-chain acyl-coA dehydrogenase; UCP2 -
uncoupling protein-2; AOX - acyl-CoA oxidase . Mean values with standard error of 
mean are shown. Statistical significance was determined by 2-way ANOVA with 
Bonferoni Post Tests or Student's T-Tests. *P<0.05, **P<0.01, ***P<0.001. 
****P<0 oooi 
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PPARa overexpression in MIN6 cells protects against palmitate-induced 
impairment of glucose stimulated insulin secretion (GSIS). 
Overexpression of PPARa in MIN6 cells in the absence of palmitate did not alter 
glucose stimulated insulin secretion (Fig. 3.4c left panel). As expected due to lipotoxic 
effects of palmitate on P-cell insulin secretion, blunted insulin levels were observed in the 
non-transfected, eGFP and PPARa MIN6 cells when treated with 250nM of palmitate 
compared to 0(iM palmitate. No significant difference was detected when comparing 
stimulation indexes of all groups (Fig. 3.4c inset). However, in the presence of palmitate, 
PPARa overexpression protected against palmitate-induced impairment of glucose-
stimulated insulin secretion (Fig. 3.4c right panel). These results are further supported by 
previous studies utilizing MIN6 and INS1-E P-cell lines (Ravnskjaer et al. 2005; 
Hellemans et al. 2007; Frigerio et al. 2010). 
Overexpression of PPARa in pancreatic p-cells protects against obesity-induced 
glucose intolerance. 
Increased PPARa overexpression was observed in the cytoplasm and nuclei in 
islets of P-PPARa-HFD mice compared to P-eGFP-HFD controls (Fig. 3a); arrows 
indicate increased nuclear staining. Fluorescent dyes were reversed (insulin green and 
PPARa red) in P-eGFP-HFD islets to ensure endogenous levels of PPARa were not 
mistaken for fluorescence from the presence of our control vector, eGFP. Sixteen weeks 
post-infection, we observed significantly improved glucose tolerance and lower overnight 
fasting blood glucose levels in diet-induced obese mice overexpressing PPARa (p-
PPARa-HFD) in pancreatic p-cells compared to diet-induced obese control mice (P-
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eGFP-HFD) (Fig. 3.5a). In fact, the improvement in glucose tolerance in p-PPARct-HFD 
mice is equal to that of age-matched, chow-fed control mice; a substantial improvement 
considering these mice have been on a HFD diet for 16 weeks (Fig. 3.5a). 
Specifically, blood glucose levels taken 10 minutes post glucose gavage were 
significantly lower in (3-PPARa-HFD (20.13 ± 0.46 mmol/L) mice compared to P-eGFP-
HFD controls (22.67 ± 0.75 mmol/L). It should be noted that although not significant 
over time, significantly lower 4 hr fasted blood glucose levels were observed in P-
PPARa-HFD mice at two significantly reduced time points (Fig. 3.5b) compared to P-
eGFP-HFD control mice. Improvements in glucose tolerance in obese P-PPARa-HFD 
mice were not associated with reduction in body weight (Fig. 3.5c) or improvement in 
whole body insulin sensitivity (Fig. 3.5d) compared to P-eGFP-HFD control mice 
suggesting improvement in insulin sensitivity did not account for the improvement in 
glucose tolerance. Moreover, a trend in improving glucose tolerance over time was also 
observed (Fig. 3.6 a-e). 
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Figure 3.5 (A) PPARa is overexpressed in the cytoplasm and nuclei (arrows) of P-
PPARa-HFD compared to P-eGFP-HFD controls. (B) Overexpression of PPARa in 
pancreatic p-cells of obese mice improved oral glucose tolerance (2g/kg D-glucose) 
compared to obese controls, with glucose tolerance similar to age-matched, chow mice. 
(C) Over time, no significant difference between 4 hr fasted blood glucose was observed. 
(D) PPARa overexpression did not affect body weight. (E), nor was insulin sensitivity 
affected (1U insulin/kg). Abbreviations: PPARa - peroxisome proliferator-activated 
receptor alpha; eGFP - enhanced green fluorescent protein; FBG - fasted blood glucose; 
HFD - high-fat diet. P-eGFP-HFD n=6, p-PPARa-HFP n=8. Mean values with SEM are 
shown. Statistical significant variation was determined by 2-way ANOVA with 
Bonferoni Post Tests or Student's T-Tests. *P<0.05, **P<0.01, ***P<0.001. 
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PPARa overexpression in pancreatic p-cells maintains 1st phase insulin secretion in 
obesity. 
Circulating insulin levels in P-PPARa-HFD (2.05 ±0.19 ng) mice were 
significantly higher than P-eGFP-HFD controls (1.05 ± 0.20 ng) 5 minutes post glucose 
gavage (Fig. 3.7a). No significant difference in fasting or refeed plasma insulin levels 
were observed (Fig. 3.7b) in P-PPARa-HFD mice compared to P-eGFP-HFD control 
mice (Fig. 3.7b). We did not observe any difference in islet morphology or p-cell mass in 
the two groups of mice (Fig. 3.7c). Additionally, Figure 3.8 shows no significant 
difference in body weight or tissue mass (liver, pancreas, gonadal white adipose, or 
subcutaneous white adipose) from either P-eGFP-HFD or P-PPARa-HFD groups, further 
suggesting that improvements in whole-body carbohydrate metabolism observed were 
associated with changes in p-cell function and not body composition. 
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Figure 3.6 Overexpression of PPARa in pancreatic P-cells shows a trend towards 
improved glucose tolerance over time (2g D-glucose/kg). Oral glucose tolerance tests 
over time (A) Baseline, (B) 1-month post-infection, (C) 2-months post-infection, (D) 3-
months post-infections (E) 4-months post infection. Abbreviations: PPARa - peroxisome 
proliferator-activated receptor alpha; eGFP - enhanced green fluorescent protein; FBG -
fasted blood glucose; HFD - high-fat diet. |3-eGFP-HFD n=6, P-PPARa-HFP n=8. Mean 
values with SEM are shown. Statistical significant variation was determined by 2-way 
ANOVA with Bonferoni Post Tests. *P<0.05, **P<0.01, ***P<0.001. 
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Figure 3.7 Overexpression of PPARa in pancreatic P-cells maintains 1st phase insulin 
secretion in C57B16 mice on high-fat diet compared to obese controls. Glucose-
stimulated insulin secretion (A) but not overnight and refeed insulin levels (B) was 
significantly affected. Additionally, overexpression of PPARa in pancreatic p-cells did 
not change islet morphology or P-cell or a-cell mass (C) when compared to obese 
controls. Abbreviations: PPARa - peroxisome proliferator-activated receptor alpha; eGFP 
- enhanced green fluorescent protein. p-eGFP-HFD n=6, p-PPARa-HFP n=8. Mean 
values with SEM are shown. Statistical significant variation was determined by 2-way 
ANOVA with Bonferoni Post Tests or Student's T-Tests. *P<0.05, **P<0.01, 
***p<0 001. Images taken at 20x magnification. Scale bar 50|im. 
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Figure 3.8 Overexpression of PPARa in pancreatic P-cells does not cause changes in 
peripheral tissue mass on HFD. Abbreviations: PPARa - peroxisome proliferator-
activated receptor alpha; eGFP - enhanced green fluorescent protein; HFD - high fat 
diet; scWAT - subcutaneous white adipose tissue; gWAT - gonodal white adipose tissue. 
(3-eGFP-HFD n=6, (3-PPARa-HFP n=8. Mean values with SEM are shown. Statistical 
significant variation was determined by student's t-tests. 
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3.4 DISCUSSION 
Our group has shown for the first time that PPARu overexpression in pancreatic 
P-cells, in vivo, improves glucose tolerance and maintains 1st phase insulin secretion on 
HFD in a diet-induced obese model of T2D. Beneficial effects of systemic PPARa 
agonism on P-cell function and carbohydrate metabolism have been demonstrated 
(Guerre-Millo et al. 2000; Holness et al. 2003; Bergeron et al. 2006), however the impact 
of P-cell-specific PPARa overexpression on whole-body carbohydrate metabolism has 
yet to be explored in an in vivo model of obesity-induced T2D. Given the pro-oxidative 
potential of PPARa, we hypothesized that specific activation of PPARa in pancreatic p-
cells of obese mice may prevent lipid-induced p-cell failure. We show in vivo 
overexpression of PPARa specifically in pancreatic P-cells significantly improves whole 
animal glucose tolerance in diet-induced obese mice to levels equal to that of age-
matched, chow-fed, control mice (Fig. 3.5a). This is a substantial improvement 
considering p-PPARa-HFD mice have been exposed to a HFD for 16 weeks and we 
would not expect improvements in glucose tolerance to exceed that of the age-matched 
chow mice. This improvement in glucose tolerance is not due to reductions in body 
weight or improvements in insulin sensitivity. Instead we show 1st phase insulin 
secretion (5 minutes post glucose-gavage) is higher in P-PPARa-HFD mice compared to 
obese control mice. In addition to improvements in glucose tolerance, we observed lower 
overnight fasted blood glucose levels with a trend of decreased 4 hr fasted blood glucose 
levels. Despite increased insulin secretion, fasting and fed plasma insulin levels were not 
significantly higher in p-PPARa-HFD mice compared to control mice. Morphological 
analysis of pancreatic tissue did not show increased P-cell mass, suggesting P-cell 
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specific PPARa overexpression improved p-cell function rather than increasing P-cell 
mass. 
Further studies are required to determine the lipidomic profile of any accumulated 
lipids within the pancreatic P-cells of both our p-eGFP-HFD and p-PPARa-HFD mice. 
Additionally experiments will need to be conducted to determine the rate of lipid 
turnover within the pancreatic P-cells, as the majority of in vivo work attributes 
improvements in whole animal carbohydrate metabolism to lipid turnover in the liver. As 
Lee et al. (2003) have suggested that the increase in liver lipid accumulation and liver 
mass in PPARa-null mice further supports PPARa's role in lipid regulation, as well the 
liver being a site of lipid turnover (Lee et al. 2003). The authors also speculated that the 
hypoglycemia, and elevated FA plasma levels observed in PPARa-null mice were caused 
by the defective FA oxidation and uptake in the liver (Lee et al. 2003). Furthermore, a 
study involving fibrate treatment in primates resulted in an increased liver mass 
associated with an increase in number of peroxisomes, resulting in an increase in p-
oxidation (Hoivik et al. 2004). Combined, these studies suggest increased liver mass 
does affect PPARa's role in lipid metabolism, which subsequently effects whole-body 
carbohydrate metabolism. Together these studies have indicated that improvements in 
whole animal carbohydrate metabolism were due to PPARa's role in lipid turnover in the 
liver. Therefore, it is important that our group rule out the liver as a possible source of 
carbohydrate improvement. As discussed in chapter 2, our group has ruled out dsAAV8-
RIP-eGFP expression in the liver tissue of infected mice; therefore we assume dsAAV8-
RIP-PPARa would not be expressed in these tissues. Moreover, as seen in figure 3.8, we 
have shown no significant difference in liver mass between P-eGFP-HFD and P-PPARa-
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HFD mice, thus we suggest improvements observed were not due to changes in liver lipid 
metabolism. This data supports our observation that improvement in glucose tolerance in 
P-PPARa-HFD mice was due to the direct action of overexpressing PPARa in the 
pancreatic P-cells and not due to peroxisome proliferation and increased PPARa activity 
in the liver. 
Utilizing ob/ob mice, Lalloyer and colleagues were able to show that PPARa 
deficiency resulted in impaired GSIS and defective islet function (Lalloyer et al. 2006), 
suggesting PPARa may play an important role in preserving p-cell function in the obese 
state. Our results support a direct role for PPARa in improving pancreatic P-cell 
function, with overexpression of PPARa specifically within the pancreatic P-cells 
maintaining 1st phase insulin secretion impaired by obesity. Frigerio and colleagues 
(2010) have performed extensive in vitro studies that support this finding. Utilizing the 
INS IE cell line, they have shown that overexpression of PPARa is able to restore 
glucose-stimulated insulin secretion in the presence of oleate (Frigerio et al. 2010), while 
downregulation of PPARa expression exacerbated lipid-induced dysfunction (Frigerio et 
al. 2010). 
As with previous studies, our group has been able to show, in vitro, that 
overexpression of PPARa has protective effects against lipotoxic dysfunction in the 
presence of palmitate, which may be due to the increased P-oxidative activity from the 
induction of PPARa target genes. When activated PPARa increases transcription of 
downstream target genes involved in P-oxidation (Mandard et al. 2004); therefore it 
would be expected that in the presence of palmitate MIN6 cells overexpressing PPARa 
would show an induction of target genes. We show in the presence of palmitate, that the 
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PPARa target gene CPT1 is significantly increased in cells overexpressing PPARa 
(Ravnskjaer et al. 2005; Hellemans et al. 2007; Frigerio et al. 2010). CPT1 was found to 
have a two-fold increase (2.4+0.30) compared to eGFP-MIN6 controls (1.0+0.18), 
similar to results obtained by Frigerio and colleagues (2010). Levels of LCAD, AOX, 
and UCP2 induction were not found to be significantly increased, therefore we must also 
consider the fact that these PPARa overexpression studies also overexpressed an 
adenovirus for RXR in addition to PPARa (Ravnskjaer et al. 2005; Hellemans et al. 
2007; Frigerio et al. 2010). Overexpressing RXR in addition to PPARa may allow for 
increased formation of the RXR-PPAR heterodimer, and subsequent increase in 
transcription of the downstream (3-oxidative genes (Fig. 3.1). 
Therefore it is quite possible that the lack of increased P-oxidative gene induction 
observed is due to an excess of PPARa in the presence of endogenous levels of RXR 
within the MIN6 cell or the appropriate activating ligand for PPARa is not present in 
sufficient quantities. However, consistent with the previous studies our group has been 
able to show the overexpressing PPARa in MIN6 cells protects against lipotoxic 
impairment of glucose-stimuated insulin secretion (GSIS), showing that in vitro PPARa 
overexpression in the presence of palmitate protects MIN6 cells and enhances glucose-
stimulated insulin secretion. These findings are consistent with previous studies that have 
shown PPARa to protect p-cells from lipid-induced impairment of GSIS in INS-IE cells 
(Ravnskjaer et al. 2005; Lalloyer et al. 2006; Sun et al. 2008; Frigerio et al. 2010). 
Frigerio and colleagues (2010) have suggested that the improvement observed with 
PPARa activation is due to an increase in glucose metabolic pathways as well as safe FA 
storage in the form of neutral lipids such as TGs (Frigerio et al. 2010). Additionally, this 
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group was able to show that downregulation of PPARa worsened oleate-induced 
dysfunction in INS-IE cells (Frigerio et al. 2010); further supporting our results that 
PPARa overexpression has protective effects against palmitate-induced dysfunction. 
The lack of upregulation of PPARa genes may be due to the fact that palmitate 
may not be the appropriate ligand for PPARa; thus trying in vitro experiments with a 
different FA such as oleate or various ceramides could be used. After reviewing the 
literature, most studies utilize palmitate as their fatty acid treatment for either their MIN6 
or INS-1 cells. Studies have shown that palmitate treatment should be kept to a 
maximum of 48 hrs before proceeding with the remainder of the desired treatments. 
Hellemans et al. (2007), Frigerio et al. (2009), and Thorn and Bergsten (2010) have done 
extensive studies showing that cellular apoptosis increases with palmitate treatments in 
excess of 48 hrs (Hellemans et al. 2007; Frigerio et al. 2010; Thorn and Bergsten 2010); 
therefore we kept our palmitate incubations to 48 hrs at a concentration of 250|iM. 
Whereas it was found that oleate was not as toxic to the MIN6 and INS-1 cells in excess 
of 48hrs (Frigerio et al 2009). 
It has been documented that the rate of turnover of human pancreatic p-cells is 
slow (Riedel et al. 2010; Skelin et al. 2010), whereas the turnover time in murine models 
is approximately 47 days (Wang et al. 2004). Wang and colleagues (2004) have 
suggested it is very likely that P-cells infected with adeno-associated viruses are lost due 
to normal maintenance and cellular apoptosis (Wang et al. 2004). Recycling rates of 
PPARa overexpressing P-cells may explain why significantly lower 4 hr fasted blood 
glucose was observed during only two weeks (no significance over time) (Fig. 3.5b) and 
why impaired glucose tolerance was not maintained. 
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Synthetic PPARa agonists, such as fibrates, are approved for human use to lower 
elevated lipid profiles in individuals with hypertriglyceridemia; further, their systemic 
administration has been shown to induce improvements in carbohydrate metabolism 
(Staels et al. 2008). Our results suggest that PPARa may have direct effects on P-cell 
function that may be contributing to the improvements in carbohydrate metabolism 
observed with systemic administration of fibrates. Our model which specifically 
upregulates PPARa activity in pancreatic P-cells is the first in vivo model of P-cell-
specific PPARa overexpression and the first model that conclusively shows P-cell 
specific effects of PPARa agonism can impact whole-animal glucose homeostasis 
independently of systemic effects on liver and muscle lipid metabolism. Furthermore, our 
study has shown that targeted delivery of PPARa to the p-cell could serve as a potential 
site for therapeutic intervention for the preservation of P-cell function, in islet 
transplantation or in the treatment of obesity-induced T2D. In conclusion, we have 
demonstrated that targeted delivery of PPARa specifically to pancreatic P-cells in vivo 
preserves P-cell function and protects against glucose intolerance in diet-induced obesity, 
thus providing a valuable in vivo model to elucidate the mechanisms involved in p-cell 
lipotoxicity in obesity-induced T2D. The major findings from this chapter are: 
1. We have developed the 1st in vivo model of PPARa overexpression in 
pancreatic P-cells to further elucidate the mechanisms involved in P-cell 
lipotoxicity in a diet-induced obese model of T2D. 
2. Overexpression of dsAAV8-RIP-PPARa in pancreatic P-cells improves 
glucose tolerance in a diet-induced obese model of T2D. 
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3. Overexpression of dsAAV8-RIP-PPARa in the pancreatic P-cells maintains 
1st phase insulin secretion impaired by obesity. 
4. Overexpression of dsAAV8-RIP-PPARa within the pancreatic P-cells does 
not affect body weight, insulin sensitivity or weight gain in peripheral tissues. 
5. Using AAV8 plasmid, PPARa overexpression in MIN6 occurs at 
physiological levels and upregulates the ^-oxidative target gene CPT1 in the 
presence of palmitate. 
6. Overexpression of PPARa plasmid in MIN6 maintains glucose-stimulated 
insulin secretion when treated with palmitate. 
104 
3.5 REFERENCES 
Bergeron, R., J. Yao, J. W. Woods, E. I. Zycband, C. Liu, Z. Li, A. Adams, J. P. Berger, 
B. B. Zhang, D. E. Moller and T. W. Doebber (2006). "Peroxisome proliferator-
activated receptor (PPAR)-alpha agonism prevents the onset of type 2 diabetes in 
Zucker diabetic fatty rats: A comparison with PPAR gamma agonism." 
Endocrinology 147(9): 4252-4262. 
Bihan, H., C. Rouault, G. Reach, V. Poitout, B. Staels and M. Guerre-Millo (2005). 
"Pancreatic islet response to hyperglycemia is dependent on peroxisome 
proliferator-activated receptor alpha (PPARalpha)." FEBS Lett 579(11): 2284-
2288. 
Bustin, S. A., V. Benes, J. A. Garson, J. Hellemans, J. Huggett, M. Kubista, R. Mueller, 
T. Nolan, M. W. Pfaffl, G. L. Shipley, J. Vandesompele and C. T. Wittwer 
(2009). "The MIQE guidelines: minimum information for publication of 
quantitative real-time PCR experiments." Clin Chem 55(4): 611-622. 
Chinetti, G., J. C. Fruchart and B. Staels (2000). "Peroxisome proliferator-activated 
receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism 
and inflammation." Inflamm Res 49(10): 497-505. 
Dalby, B., S. Cates, A. Harris, E. C. Ohki, M. L. Tilkins, P. J. Price and V. C. Ciccarone 
(2004). "Advanced transfection with Lipofectamine 2000 reagent: primary 
neurons, siRNA, and high-throughput applications." Methods 33(2): 95-103. 
Eisner, M., W. Gehrmann and S. Lenzen (2011). "Peroxisome-generated hydrogen 
peroxide as important mediator of lipotoxicity in insulin-producing cells." 
Diabetes 60(1): 200-208. 
Frederiksen, K. S., E. M. Wulff, P. Sauerberg, J. P. Mogensen, L. Jeppesen and J. 
Fleckner (2004). "Prediction of PPAR-alpha ligand-mediated physiological 
changes using gene expression profiles." J Lipid Res 45(3): 592-601. 
Frigerio, F., T. Brun, C. Bartley, A. Usardi, D. Bosco, K. Ravnskjaer, S. Mandrup and P. 
Maechler (2010). "Peroxisome proliferator-activated receptor alpha (PPARalpha) 
protects against oleate-induced INS-IE beta cell dysfunction by preserving 
carbohydrate metabolism." Diabetologia 53(2): 331-340. 
Gehrmann, W., M. Eisner and S. Lenzen (2010). "Role of metabolically generated 
reactive oxygen species for lipotoxicity in pancreatic beta-cells." Diabetes Obes 
Metab 12 Suppl 2: 149-158. 
Giacca, A., C. Xiao, A. I. Oprescu, A. C. Carpentier and G. F. Lewis (2011). "Lipid-
induced pancreatic beta-cell dysfunction: focus on in vivo studies." Am J Physiol 
Endocrinol Metab 300(2): E255-262. 
105 
Gonzalez, F. J., J. M. Peters and R. C. Cattley (1998). "Mechanism of action of the 
nongenotoxic peroxisome proliferators: role of the peroxisome proliferator-
activator receptor alpha." J Natl Cancer Inst 90(22): 1702-1709. 
Guerre-Millo, M., P. Gervois, E. Raspe, L. Madsen, P. Poulain, B. Derudas, J. M. 
Herbert, D. A. Winegar, T. M. Willson, J. C. Fruchart, R. K. Berge and B. Staels 
(2000). "Peroxisome proliferator-activated receptor alpha activators improve 
insulin sensitivity and reduce adiposity." J Biol Chem 275(22): 16638-16642. 
Guerre-Millo, M., C. Rouault, P. Poulain, J. Andre, V. Poitout, J. M. Peters, F. J. 
Gonzalez, J. C. Fruchart, G. Reach and B. Staels (2001). "PPAR-alpha-null mice 
are protected from high-fat diet-induced insulin resistance." Diabetes 50(12): 
2809-2814. 
Gwiazda, K. S., T. L. Yang, Y. Lin and J. D. Johnson (2009). "Effects of palmitate on ER 
and cytosolic Ca2+ homeostasis in beta-cells." Am J Physiol Endocrinol Metab 
296(4): E690-701. 
Hellemans, K., K. Kerckhofs, J. C. Hannaert, G. Martens, P. Van Veldhoven and D. 
Pipeleers (2007). "Peroxisome proliferator-activated receptor alpha-retinoid X 
receptor agonists induce beta-cell protection against palmitate toxicity." FEBS J 
274(23): 6094-6105. 
Hoivik, D. J., C. W. Quails, Jr., R. C. Mirabile, N. F. Cariello, C. L. Kimbrough, H. M. 
Colton, S. P. Anderson, M. J. Santostefano, R. J. Morgan, R. R. Dahl, A. R. 
Brown, Z. Zhao, P. N. Mudd, Jr., W. B. Oliver, Jr., H. R. Brown and R. T. Miller 
(2004). "Fibrates induce hepatic peroxisome and mitochondrial proliferation 
without overt evidence of cellular proliferation and oxidative stress in 
cynomolgus monkeys." Carcinogenesis 25(9): 1757-1769. 
Holness, M. J., N. D. Smith, G. K. Greenwood and M. C. Sugden (2003). "Acute (24 h) 
activation of peroxisome proliferator-activated receptor-alpha (PPARalpha) 
reverses high-fat feeding-induced insulin hypersecretion in vivo and in perifiised 
pancreatic islets." J Endocrinol 177(2): 197-205. 
Huynh, F. K., J. Levi, H. C. Denroche, S. L. Gray, P. J. Voshol, U. H. Neumann, M. 
Speck, S. C. Chua, S. D. Covey and T. J. Kieffer (2010). "Disruption of hepatic 
leptin signaling protects mice from age- and diet-related glucose intolerance." 
Diabetes 59(12): 3032-3040. 
Kersten, S., J. Seydoux, J. M. Peters, F. J. Gonzalez, B. Desvergne and W. Wahli (1999). 
"Peroxisome proliferator-activated receptor alpha mediates the adaptive response 
to fasting." J Clin Invest 103(11): 1489-1498. 
106 
Koh, E. H., M. S. Kim, J. Y. Park, H. S. Kim, J. Y. Youn, H. S. Park, J. H. Youn and K. 
U. Lee (2003). "Peroxisome proliferator-activated receptor (PPAR)-alpha 
activation prevents diabetes in OLETF rats: comparison with PPAR-gamma 
activation." Diabetes 52(9): 2331-2337. 
Koves, T. R., J. R. Ussher, R. C. Noland, D. Slentz, M. Mosedale, O. Ilkayeva, J. Bain, 
R. Stevens, J. R. Dyck, C. B. Newgard, G. D. Lopaschuk and D. M. Muoio 
(2008). "Mitochondrial overload and incomplete fatty acid oxidation contribute to 
skeletal muscle insulin resistance." Cell Metab 7(1): 45-56. 
Lalloyer, F., B. Vandewalle, F. Percevault, G. Torpier, J. Kerr-Conte, M. Oosterveer, R. 
Paumelle, J. C. Fruchart, F. Kuipers, F. Pattou, C. Fievet and B. Staels (2006). 
"Peroxisome proliferator-activated receptor alpha improves pancreatic adaptation 
to insulin resistance in obese mice and reduces lipotoxicity in human islets." 
Diabetes 55(6): 1605-1613. 
Lee, C. H., P. Olson and R. M. Evans (2003). "Minireview: lipid metabolism, metabolic 
diseases, and peroxisome proliferator-activated receptors." Endocrinology 144(6): 
2201-2207. 
Loh, K., H. Deng, A. Fukushima, X. Cai, B. Boivin, S. Galic, C. Bruce, B. J. Shields, B. 
Skiba, L. M. Ooms, N. Stepto, B. Wu, C. A. Mitchell, N. K. Tonks, M. J. Watt, 
M. A. Febbraio, P. J. Crack, S. Andrikopoulos and T. Tiganis (2009). "Reactive 
oxygen species enhance insulin sensitivity." Cell Metab 10(4): 260-272. 
Mandard, S., M. Muller and S. Kersten (2004). "Peroxisome proliferator-activated 
receptor alpha target genes." Cell Mol Life Sci 61(4): 393-416. 
Medina-Gomez, G., S. L. Gray, L. Yetukuri, K. Shimomura, S. Virtue, M. Campbell, R. 
K. Curtis, M. Jimenez-Linan, M. Blount, G. S. Yeo, M. Lopez, T. Seppanen-
Laakso, F. M. Ashcroft, M. Oresic and A. Vidal-Puig (2007). "PPAR gamma 2 
prevents lipotoxicity by controlling adipose tissue expandability and peripheral 
lipid metabolism." PLoS Genet 3(4): e64. 
Oprescu, A. I., G. Bikopoulos, A. Naassan, E. M. Allister, C. Tang, E. Park, H. Uchino, 
G. F. Lewis, I. G. Fantus, M. Rozakis-Adcock, M. B. Wheeler and A. Giacca 
(2007). "Free fatty acid-induced reduction in glucose-stimulated insulin secretion: 
evidence for a role of oxidative stress in vitro and in vivo." Diabetes 56(12): 
2927-2937. 
Qin, Y. M., M. H. Poutanen, H. M. Helander, A. P. Kvist, K. M. Siivari, W. Schmitz, E. 
Conzelmann, U. Hellman and J. K. Hiltunen (1997). "Peroxisomal 
multifunctional enzyme of beta-oxidation metabolizing D-3-hydroxyacyl-CoA 
esters in rat liver; molecular cloning, expression and characterization." Biochem J 
321 (Pt 1): 21-28. 
107 
Ravnskjaer, K., M. Boergesen, B. Rubi, J. K. Larsen, T. Nielsen, J. Fridriksson, P. 
Maechler and S. Mandrup (2005). "Peroxisome proliferator-activated receptor 
alpha (PPARalpha) potentiates, whereas PPARgamma attenuates, glucose-
stimulated insulin secretion in pancreatic beta-cells." Endocrinology 146(8): 
3266-3276. 
Reddy, J. K. and T. Hashimoto (2001). "Peroxisomal beta-oxidation and peroxisome 
proliferator-activated receptor alpha: an adaptive metabolic system." Annu Rev 
Nutr 21: 193-230. 
Riedel, M. J., D. F. Gaddy, A. Asadi, P. D. Robbins and T. J. Kieffer (2010). "DsAAV8-
mediated expression of glucagon-like peptide-1 in pancreatic beta-cells 
ameliorates streptozotocin-induced diabetes." Gene Ther 17(2): 171-180. 
Skelin, M., M. Rupnik and A. Cencic (2010). "Pancreatic beta cell lines and their 
applications in diabetes mellitus research." ALTEX 27(2): 105-113. 
Staels, B., M. Maes and A. Zambon (2008). "Fibrates and future PPARalpha agonists in 
the treatment of cardiovascular disease." Nat Clin Pract Cardiovasc Med 5(9): 
542-553. 
Sugden, M. C., G. K. Greenwood, N. D. Smith and M. J. Holness (2003). "Peroxisome 
proliferator-activated receptor-alpha activation during pregnancy attenuates 
glucose-stimulated insulin hypersecretion in vivo by increasing insulin sensitivity, 
without impairing pregnancy-induced increases in beta-cell glucose sensing and 
responsiveness." Endocrinology 144(1): 146-153. 
Sun, Y., L. Zhang, H. F. Gu, W. Han, M. Ren, F. Wang, B. Gong, L. Wang, H. Guo, W. 
Xin, J. Zhao and L. Gao (2008). "Peroxisome proliferator-activated receptor-alpha 
regulates the expression of pancreatic/duodenal homeobox-1 in rat insulinoma 
(INS-1) cells and ameliorates glucose-induced insulin secretion impaired by 
palmitate." Endocrinology 149(2): 662-671. 
Thorn, K. and P. Bergsten (2010). "Fatty acid-induced oxidation and triglyceride 
formation is higher in insulin-producing MIN6 cells exposed to oleate compared 
to palmitate." J Cell Biochem 111(2): 497-507. 
Tordjman, K., K. N. Standley, C. Bernal-Mizrachi, T. C. Leone, T. Coleman, D. P. Kelly 
and C. F. Semenkovich (2002). "PPARalpha suppresses insulin secretion and 
induces UCP2 in insulinoma cells." J Lipid Res 43(6): 936-943. 
Virtue, S. and A. Vidal-Puig (2010). "Adipose tissue expandability, lipotoxicity and the 
Metabolic Syndrome—an allostatic perspective." Biochim Biophvs Acta 1801(3): 
338-349. 
108 
Wang, A. Y., P. D. Peng, A. Ehrhardt, T. A. Storm and M. A. Kay (2004). "Comparison 
of adenoviral and adeno-associated viral vectors for pancreatic gene delivery in 
vivo." Hum Gene Ther 15(4): 405-413. 
Xiao, C., A. Giacca and G. F. Lewis (2008). "Oral taurine but not N-acetylcysteine 
ameliorates NEFA-induced impairment in insulin sensitivity and beta cell 
function in obese and overweight, non-diabetic men." Diabetologia 51(1): 139-
146. 
Xiao, J., S. Gregersen, M. Kruhoffer, S. B. Pedersen, T. F. Orntoft and K. Hermansen 
(2001). "The effect of chronic exposure to fatty acids on gene expression in clonal 
insulin-producing cells: studies using high density oligonucleotide microarray." 
Endocrinology 142(11): 4777-4784. 
Yajima, K., H. Hirose, H. Fujita, Y. Seto, K. Ukeda, K. Miyashita, T. Kawai, Y. 
Yamamoto, T. Ogawa, T. Yamada and T. Saruta (2003). "Combination therapy 
with PPARgamma and PPARalpha agonists increases glucose-stimulated insulin 
secretion in db/db mice." Am J Physiol Endocrinol Metab 284(5): E966-971. 
Yessoufou, A., J. M. Ategbo, E. Attakpa, A. Hichami, K. Moutairou, K. L. Dramane and 
N. A. Khan (2009). "Peroxisome proliferator-activated receptor-alpha modulates 
insulin gene transcription factors and inflammation in adipose tissues in mice." 
Mol Cell Biochem 323(1-2): 101-111. 
109 
APPENDIX 
Figure SI. Transfection efficiency of MIN6-eGFP cells. (A) 30% efficiency; 1 day post-
transfection. (B) 50-60% efficiency; 2 days post-transfection. Image taken with FITC 
filter at lOx magnification using confocal microscope (Olympus). 
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Figure S2. RNA Quality Control Gel for MIN6-eGFP and MIN6-PPARa Transfected 
Cells. Running Conditions (1.5% Agarose, lx TAE Running Buffer, 100V, 1 hour, 
Stained with EtBr). All samples show clean 18S and 28S bands indicating no 
degradation of RNA collected from the transfected MIN6 cells. 
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Figure S3. Double Restriction Digests of Purified Plasmid Samples for Viral Construct 
Preparation. Restriction digests were run using no digest, pure plasmid, and 1:10 dilution 
of plasmid. Restriction Enzymes for eGFP (Mlul and NotI), PPARa (Hindlll and Mlul). 
Running Conditions (1.5% Agarose, 0.5x TBE Running Buffer, 100V, 1 hour, Stained 
with SYBR Safe). 
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CHAPTER 4 
Overexpression of PPARa in Pancreatic p-cells Does Not Improve Glucose 
Tolerance in a Severely Obese Genetic Model (db/db mouse). 
A version of this chapter has been submitted: 
Hogh, K-Lynn N., Uy, Christopher E., Asadi, A., Baker, Robert K., Riedel, Michael J., 
Gray, Sarah L. 2012. Overexpression of PPARa in pancreatic P-cells improves glucose 
tolerance in diet-induced obese mice. Endocrinology. Manuscript Submission number: 
EN-12-1110. 
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4.1 INTRODUCTION 
Animals have been used in diabetes research as early as the 1880's (Rees and 
Alcolado 2005). The use of animals was best exemplified by Banting and Best in the 
1920's, when they used pancreatectomized dogs for the isolation and discovery of insulin 
(Banting et al. 1922; Bliss 1982; Rosenfeld 2002; Rees and Alcolado 2005). The use of 
mouse models in research has become increasingly important to elucidate the 
mechanisms involved in the progression of obesity-induced T2D. In addition to the diet-
induced obese model of T2D (C57B16 mice on HFD) used in chapter three, there are 
various obese and non-obese rodent models utilized in diabetes research, including: i) 
spontaneous/genetically derived (ie. ob/ob and db/db), ii) diet-induced (ie. C57B16), iii) 
chemically induced (ie. alloxan or streptozotocin), iv) surgically induced (ie. lesion of 
ventromedial hypothalamus), and v) transgenic/knock-out mice (ie. 03, GLUT-4, and 
IRS-1) (Rees and Alcolado 2005; Srinivasan and Ramarao 2007; Shafrir and Ziv 2009). 
As our lab is interested in elucidating the mechanisms involved in P-cell lipotoxicity and 
obesity-induced T2D, the severely obese ob/ob or db/db mouse models (Fig 4.1) are most 
appropriate for future studies involving the overexpression of PPARa in pancreatic P-
cells. Phenotypically the ob/ob and db/db mice are severely obese, hyperphagic, insulin 
resistant, hyperinsulinemic and hyperglycemic (Coleman and Hummel 1967; Coleman 
and Hummel 1973; Srinivasan and Ramarao 2007). Both of these mouse models involve 
either a mutation in the leptin gene (ob/ob) or leptin receptor (db/db) (Coleman and 
Hummel 1967; Coleman and Hummel 1973). 
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Figure 4.1 Comparing male C57B16 littermate controls to db/db (A) and ob/ob (B) mice. 
Mice purchased from JAX laboratories at four weeks of age. Images from Jackson 
Laboratories website: http://jaxmice.jax.org [electronic document] accessed Dec 15 2011. 
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The adipocyte-derived hormone leptin acts on the central nervous system and 
peripheral tissues to reduce fat stores by suppressing appetite, increasing metabolic rate, 
and activating thermogenesis (Muoio and Lynis Dohm 2002; Ceddia 2005; Unger 2005; 
Zhao et al. 2006; Gray and Vidal-Puig 2007; Friedman 2010). In a negative feedback 
loop, leptin acts on the receptors of the hypothalamus to regulate appetite and energy 
homeostasis (Friedman 2010); where increases in adiposity results in increased leptin 
levels and vice versa (Schroeder-Gloeckler et al. 2007; Friedman 2010). Leptin has also 
been implicated to have direct effects on glucose metabolism similar to that of insulin 
(Huynh et al. 2010). Kieffer and colleagues (1997) utilized patch clamps in ob/ob mice 
to show that leptin reduces insulin secretion through the activation of the KATP channels 
in the P-cells of the pancreas (Kieffer et al. 1997). These results were further supported 
by the work completed by Lee and Romsos (2003), where the authors were able to show 
that when treated with exogenous leptin, hypersecretion of insulin was normalized in 
ob/ob mice (Lee and Romsos 2003). Further adding to leptin's role in P-cell function, 
studies involving leptin therapy have shown a reversal in hyperglycemia in diabetic 
mouse models (Chinookoswong et al. 1999; Hidaka et al. 2002; Wang et al. 2010; 
Denroche et al. 2011) by lowering blood glucose and plasma insulin without affecting 
body weight (Kulkarni et al. 1997; Seufert et al. 1999; Gray et al. 2010). Clinically, 
Farooqi et al. (1999) were able to show that administration of recombinant leptin in 
humans reduces body weight and decreases food intake, as seen with their nine-year old 
patient with a frame-shift mutation in the leptin gene (Farooqi et al. 1999). This study 
further confirmed the importance of leptin in energy balance and appetite regulation 
(Farooqi et al. 1999). 
117 
The discovery of naturally occurring leptin mutations in mice has provided to be a 
useful tool in diabetes research, as it provides to be a model of severe obesity and 
diabetes. Leptin deficient (ob/ob) and leptin receptor deficient (db/db) mice were 
characterized by George Snell and Doug Coleman and colleagues from the Jackson 
Laboratories between 1950 and 1970 (Coleman and Hummel 1967; Coleman and 
Hummel 1973; Friedman 2010). Collectively the ob/ob and db/db mice show highly 
elevated plasma insulin levels, severely increased body mass, hyperphagia, no satiety, 
and hyperglycemia as early as three to four weeks of age (Coleman and Hummel 1967; 
Coleman and Hummel 1973; Zhang et al. 1994; Kobayashi et al. 2000). In 1994, Zhang 
and colleagues utilized positional cloning in C57B16 and DBA/2JA mice to determine 
that ob gene product was involved in the regulation of body fat deposition (Zhang et al. 
1994). More importantly, this study identified the ob gene as the leptin gene (Zhang et 
al. 1994). 
The ob/ob mouse is characterized by a mutation in the ob gene, which results in 
severe obesity through the disruption of the leptin signaling pathway (Zhang et al. 1994; 
Farooqi et al. 2002). The ob/ob mouse is characterized by an autosomal recessive 
mutation on chromosome 6 on the ob gene (Coleman and Hummel 1973; Srinivasan and 
Ramarao 2007). In addition to severe obesity, ob/ob mice develop extreme 
hyperglycemia and hyperinsulinemia by nine weeks of age, which results in hypertrophy 
and degranulation of pancreatic p-cells (Coleman and Hummel 1973; Srinivasan and 
Ramarao 2007). Interestingly, the ob/ob mice have also been observed to have transient 
hyperglycemia, followed by hyperinsulinemia and euglycemia (Coleman and Hummel 
1973). 
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In contrast to the ob/ob mouse, the db/db model is characterized by severe 
obesity, hyperinsulinemia, hyperglycemia, and dyslipidemia as early as three weeks of 
age (Coleman and Hummel 1967; Kieffer and Habener 2000). The db/db mutation is 
characterized by an autosomal recessive mutation on chromosome 4 of the db gene 
(Coleman and Hummel 1967; Srinivasan and Ramarao 2007; Shafrir and Ziv 2009), 
resulting in a defective leptin receptor encoded by the db gene (Coleman and Hummel 
1967; Friedman 2010). It should be noted that degranulation and increased apoptosis can 
be observed as early as 25 days after birth in db/db islets (Coleman and Hummel 1967; 
Kobayashi et al. 2000). Additionally islets of db/db mice have been observed to fail via 
increased pancreatic necrosis and atrophy (Coleman and Hummel 1967; Kobayashi et al. 
2000; Shafrir and Ziv 2009), thus resulting in end-stage p-cell failure. Therefore, as the 
severity of obesity and development of the diabetic phenotype occurs at an early age in 
both ob/ob and db/db mice, these mouse models are ideal for short-term studies 
elucidating the mechanisms involved in P-cell lipotoxicity, severe obesity and diabetes. 
The objective of this study is to utilize the db/db model of genetic obesity to 
replicate and tease apart the observations made in our model of P-cell specific 
overexpression of PPARa in a diet-induced model of obesity and T2D. We hypothesize 
that overexpression of PPARa in the pancreatic P-cells of db/db mice will delay the 
progression and severity of P-cell dysfunction in these mice compared to $-e,GY?-db/db 
controls. Additionally, this study will allow us to test the effectiveness and potency of 
PPARa overexpression in a severe model of genetic obesity; thus further characterizing 
the role of PPARa overexpression in pancreatic P-cells in vivo. 
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4.2 MATERIALS AND METHODS 
Mice. 
All animal studies were approved by the University of Northern British Columbia 
Animal Care and Use Committee (protocol number 2011-21). For all experiments, 3-
week-old, male, C57B16 mice (littermate controls) and db/db mice (BKS.Cg-w +/+ 
LeprdbIJ) were purchased from Jackson Laboratories (Bar Harbor ME, USA). Mice were 
maintained on a 12 hr light/dark cycle and received standard rodent chow diet (Rodent 
LabDiet, 5001, Leduc AB, Canada) ad libitum unless otherwise stated. Mice were 
allowed to acclimatize to the animal facility for 1 week prior to performing any 
experimental procedures. Body weight, 4hr fasted blood glucose (OneTouch Ultra, 
Lifescan, Burnaby BC, Canada), oral glucose tolerance tests (via OGTT) and insulin 
sensitivity tests (via ITT) were performed prior to viral injections to assess baseline 
carbohydrate metabolism as described below and in chapter 3. 
Pancreatic p-cell specific overexpression of PPARa in genetically obese mice. 
Six-week-old male db/db mice were infected with dsAAV8-RIP-PPARa adeno-
associated virus (P-PPARa-t/M/6, n=6; 5x1012 viral genomes/5 83 (il/mouse) or dsAAV8-
RIP-eGFP virus (p-eGFP-db/db control group, n=7; 5x1012 viral genomes/574(xl/mouse) 
by ip injection. A group of age-matched, male, wildtype, C57B16 mice were given an ip 
injection of saline to serve as lean controls (n=7; 574^1 saline/mouse). Body weight was 
monitored weekly, and blood glucose levels (OneTouch Ultra, Lifescan Burnaby BC, 
Canada) and circulating plasma insulin levels (ALPCO) were monitored twice weekly. 
Insulin sensitivity (ITT) was also assessed. All animals were sacrificed 4 weeks post­
infection by C02 euthanization and cerebral-spinal dislocation. Tissues were collected 
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by dissection and flash frozen or fixed in 4% paraformaldehyde in IX PBS for 48 hrs and 
then stored in 70% EtOH. 
Insulin tolerance tests. 
Mice were fasted for 4 hrs and given an ip injection of human synthetic insulin at 
0.75U/kg or l.OU/kg (Novolin Ge, Toronto ON, Canada). Blood was sampled (1-2 ^1) 
from the saphenous vein and blood glucose measured (mmol/L) at 10, 20 30, 60, and 120 
min post injection (OneTouch Ultra, Lifescan Burnaby BC, Canada). 
Glucose-stimulated insulin secretion. 
Mice were fasted for 16 hrs and given 2g/kg D-glucose by oral gavage. Blood 
(15-20 |il) was sampled at 5, 10 and 180 minutes post glucose gavage from the saphenous 
vein and blood glucose (mmol/L) (OneTouch Ultra, Lifescan, Burnaby BC, Canada) 
(Huynh et al. 2010). 
Overnight fasted and re-fed plasma insulin levels. 
Mice were fasted for 16 hrs and blood collected in heparinized capillary tubes 
(Fisher Scientific, Ottawa ON, Canada) from the saphenous vein. Food was reintroduced 
for 2 hrs and blood collected again. Blood glucose was determined using a hand held 
glucometer (OneTouch Ultra, Lifescan, Burnaby BC, Canada) and plasma insulin levels 
were assessed by ELISA. 5(^1 of each sample was run in triplicate with conjugate buffer 
(75^1) and shaken at 800rpm on a microplate shaker for 2 hrs at room temperature. 
Samples were then washed with wash buffer and incubated for 15 min at 800rpm with 
TMB substrate. Stop solution was then added to samples and quantified at 450nm on a 
plate reader (Ultrasensitive insulin ELISA assay, 80-INSMSU-E10, ALPCO, Salem NH, 
USA). 
121 
Immunohistological analysis. 
Whole mouse pancreas sections were previously fixed in 4% paraformaldehyde 
and embedded in paraffin and sectioned at 5|am thickness; n=5 per group (Wax-it 
Histology Services; Vancouver BC, Canada). All sections were de-paraffinized and 
rehydrated as described previously in chapters 2 and 3(Riedel et al. 2010). Sections were 
incubated with polyclonal primary antibodies to rabbit anti-eGFP (1:500) (Al 1122, 
Invitrogen Molecular Probes, Carlsbad CA, USA), polyclonal guinea pig anti-insulin 
(1:1000) (4011-01F, Millipore, Billerica MA, USA) and a monoclonal primary antibody 
to mouse anti-glucagon (1:1000) (G2654, Sigma) overnight. Appropriate secondary 
whole (heavy and light chain) antibodies conjugated to Alexafluor 488 (A21206 or 
A21202) or 594 (Al 1076 or Al 1032) (1:1000) (Invitrogen Molecular Probes) were used 
to detect primary antibody immunoreactivity. All sections were blocked using serum-
free blocking solution (DAKO, Burlington ON, Canada) and heat-induced antigen 
retrieval performed using 6M citrate buffer. All samples were visualized using a 
fluorescent light microscope (Olympus BX61) and images observed using Cell Sens 
Software (Olympus, Markham ON, Canada). 
Statistical analysts. 
Results are expressed as mean ± standard error of the mean. Analyses were 
performed using paired student's t-test and 1-way ANOVA (significance between two 
groups), or 2-way ANOVAs (significance between groups over time) with Bonferoni 
Post tests using Graphpad Prism 5.0 software (La Jolla CA, USA). Significance was 
declared if p-values were less than 0.05. *P<0.05, **P<0.01, ***P<0.001. 
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4.3 RESULTS 
Overexpression of PPARa in pancreatic p-cells does not improve carbohydrate 
metabolism in a model of severe genetic obesity {db/db). 
P-eGFP-db/db control mice and p-PPARa-db/db mice had no significant 
difference for 2 hr fed blood glucose levels (Fig. 4.2a). PPARa overexpression 
specifically in pancreatic p-cells did not significantly affect body weight (Fig. 4.2b), or 
plasma (circulating) insulin levels (Fig. 4.2c) when compared to obese controls. As 
expected, both fasted and fed blood glucose and plasma insulin levels of P-eGFP-db/db 
and fy-WARst-db/db mice were significantly higher compared to C57B16 littermate 
controls. Additionally insulin sensitivity did not differ between groups, however as 
expected, both P-eGFP-db/db and P-PPARa-db/db are significantly more insulin resistant 
than the wild type controls (Fig. 4.2d). As expected with the insulin sensitivity (ITT) the 
wild type controls had a 50% reduction in blood glucose (10 minutes post insulin 
injection) and by 30 minutes post infection blood glucose levels were on the rise. The 
complete opposite was observed with the P-eGFP-db/db and p-PPARa-db/db mice, 
where a spike in blood glucose levels was observed 10 minutes post-injection; this rise in 
blood glucose could be attributed to their severe insulin resistance as well as an increase 
in counter regulatory and stress hormones. 
123 
Figure 4.2 Overexpression of PPARa in p-cells of genetically obese mice (db/db) did not 
improve glucose homeostasis. (A) Fast and fed blood glucose levels. (B) body weight, 
(C) plasma insulin levels, and (D) insulin sensitivity (0.75U/kg insulin for wild-type 
mice; 1.5U/kg insulin for db/db mice) in db/db mice. -db/db n=7, p-PPARa-
db/db n=6. *P<0.05. 
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Overexpression of PPARa in pancreatic p-cells does not affect islet morphology in 
genetically obese mice (db/db) 
Immunohistochemical analysis of insulin and glucagon in pancreatic p-cells 
overexpressing PPARa did not reveal any difference in insulin or glucagon positive 
immunoreactivity when compared to p-eGFP-db/db controls (Fig. 4.3). Additionally, 
islets were stained for eGFP/insulin and eGFP/glucagon immunoreactivity (Fig. 4.4) 
showing eGFP expression in islets of the db/db mice four weeks post infection. It has 
been suggested that dsAAV8 vectors do not elicit an immune response (Gao et al. 2002; 
Wang et al. 2006; Gaddy et al. 2010), however further analysis using appropriate 
apoptotic staining is required to confirm these results in db/db mice. Furthermore, total 
insulin and glucagon positive stained areas were not analyzed as no physiological 
changes were observed, therefore p-cell and a-cell masses were not calculated. 
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Figure 4.3 Overexpression of PPARa in P-cells of genetically obese mice (db/db) does 
not affect islet morphology of insulin immuno-positive area. Abbreviations: INS -
insulin; GLC - glucagon. Images taken at 20x magnification. Scale bar 50|am. 
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Figure 4.4 Overexpression of dsAAV8-RIP-eGFP in P-cells of genetically obese mice 
(idb/db) is targeted to the P-cells and not a-cells of pancreatic islets. Abbreviations: INS -
insulin; GLC - glucagon; GFP - green fluorescent protein. Images taken at 20x 
magnification. Scale bar 50(im. 
129 
0£I  
UJTIOS 
4.4 DISCUSSION 
Utilizing a genetic model of severe obesity, specifically a mutation with the leptin 
receptor (db/db mice), our group characterized the effects of p-cell specific 
overexpression of PPARa to ascertain if improvements seen with glucose tolerance in a 
HFD model of obesity would be observed in a more severe model of genetic obesity. 
Our group has demonstrated that overxpressing PPARa in the pancreatic P-cells of db/db 
mice has no protective effects against P-cell dysfunction when compared to P-eGFP-
db/db controls. This study was carried out for a total of four weeks, where mice were 
infected for four weeks prior to collection. We speculate that the lack of protective 
effects observed in this model compared to the diet-induced model maybe; i) the db/db 
model of obesity is too severe and the levels of circulating TGs and FAs have 
overwhelmed the P-cell causing p-cell dysfunction, ii) p-cells of the db/db mice are 
severely impaired and have reached P-cell failure, and iii) four weeks of overexpression 
is too short to see the beneficial effects of PPARa observed in our diet-induced model. 
Gaddy and colleagues (2010) utilized the db/db mouse model to determine if 
expression of GLP-1 via dsAAV8 to the pancreatic P-cells improves the diabetic state 
(Gaddy et al. 2010). AAV direct targeting of GLP-1 in the P-cells has been shown 
previously to enhance islet proliferation and delay the progression of diabetes in db/db 
mice (Gaddy et al. 2010). Additionally, the authors used a dose of 4xlOnvg/mouse for 
their db/db mice and speculated that increasing the viral dose (greater than 10l2vg/mouse) 
would greatly enhance the efficacy of viral transduction compensating for increased body 
mass of db/db mice (Gaddy et al. 2010). Therefore, improvements in glucose tolerance 
may have been observed in P-PPARa-db/db mice had we increased the viral load per 
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mouse, as opposed to giving the standard 5xl012 vg/mouse. Additionally it has been 
suggested that the effectiveness of dsAAV8 virus delivery can be seen as early as four 
weeks post infection (Wu et al. 2006). We have conclusively shown in chapter 2, that 
eGFP is expressed in the pancreatic P-cells as early as three weeks post infection when 
utilizing dsAAV8-RIP-eGFP. Moreover, we have shown eGFP to be expressed in the 
pancreatic p-cells in db/db mice four weeks post infection (Fig. 4.4). Therefore it is 
possible that PPARa expression is present in the islets of db/db mice; however, as the 
duration of our study lasted four weeks post infection, the physiological effects and 
beneficial potential of PPARa overexpression may not have been observed. For example 
we would expect PPARa overexpression to turn on genes involved in P-oxidation, but 
was the duration long enough to decrease the amount of circulating lipids? 
We speculate that had we extended the db/db study by four to six weeks, 
improvements similar to those observed in P-PPARa-HFD mice may have been 
observed. The severity of the db/db phenotype was an indicator to terminate the study 
four weeks post infection. As shown in figure 4.2 a-c, blood glucose levels, body 
weights, circulating plasma insulin were significantly higher than age-matched C57B16 
littermate controls; indicating that the health of the pancreatic P-cells in the db/db mice 
were getting progressively worse. Both p-eGFP-db/db and P-PPARa-db/db mice showed 
severe insulin resistance when compared to C57B16 littermate controls (Fig. 4.2d); as 
blood glucose levels reached highs of 24.5mmol/L versus dropping to 4.8mmol/L 
(C57B16) post insulin injection. Moreover, it should be noted that a glucose tolerance 
test (OGTT) was not conducted on the db/db mice due to the severity of their phenotype; 
additionally we would have expected glucose levels post gavage to be extremely high, 
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and possibly too high to be detected by a handheld glucometer, given the rise in blood 
glucose levels observed when mice were challenged with 1,5U/kg of insulin (Fig. 4.2d). 
It should also be noted that due to a lack of physiological changes observed, further 
metabolic and immunohistochemical analyses of these islets was not performed. 
The whole body improvement in carbohydrate metabolism achieved with 
pancreatic p-cell specific overexpression of PPARa in a diet-induced model of obesity 
was not replicated in the severely obese, diabetic db/db mouse. The severely impaired 
carbohydrate metabolism of this genetic model of obesity was not reversed by four weeks 
of |3-cell specific overexpression of PPARa, suggesting that the short duration of PPARa 
overexpression may not have been sufficient to improve P-cell function or that the 
metabolic changes induced by PPARa by four weeks of overexpression could not 
overcome the extreme insulin resistance and lipidemic state induced by the lack of leptin 
signaling in these severely obese and diabetic mice. 
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CHAPTER 5 
Developing a model of PPARa overexpression in the pancreatic P-cells in vivo: 
concluding remarks, future directions and significance 
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5.1 CONCLUDING REMARKS 
It has been well established that lipotoxicity is an underlying mechanism involved 
in P-cell dysfunction and obesity-induced T2D (Kasuga 2006; Prentki and Nolan 2006; 
Poitout and Robertson 2008). Moreover, obesity, its associated comorbities and T2D 
have reached epidemic levels in the past few years and are placing an overwhelming 
economic burden on health care systems worldwide (Dixon 2010). Therefore it is 
important to elucidate the mechanisms involved in obesity-induced p-cell lipotoxicity to 
postulate appropriate treatment strategies, and new therapeutic paradigms. 
Our group is the first to have developed a new in vivo mouse model of P-cell 
specific overexpression of PPARa in obesity-induced P-cell lipotoxicity. Utilizing 
dsAAV8 as our tool of gene delivery we have avoided potential complications of 
utilizing transgenic mouse models (outlined in chapter 2). Furthermore, our study has 
provided insight into the direct in vivo effects of PPARa overexpression in the pancreatic 
p-cells and its impact in whole-animal carbohydrate metabolism. In addition, our lab has 
developed a model to study lipotoxic changes in the metabolism directly in the pancreatic 
P-cells. Having shown improved glucose tolerance and maintained 1SI phase insulin 
secretion, there is the possibility of using dsAAV8 delivered PPARa as a preventable 
therapeutic for preserving P-cell function in obesity-induced T2D. Moreover, it is likely 
to utilize PPARa treated isolated islets as a preventable therapeutic for islet 
transplantation; further protecting the islets from lipid accumulation and increasing the 
longevity of transplanted islets. 
Taken together, our findings have provided new insights and advancements for future 
studies involving in vivo PPARa overexpression in P-cell lipotoxicity. We have 
139 
developed an in vivo mouse model that can be utilized to elucidate the protective role of 
PPARa in p-cell dysfunction and lipotoxicity, as well as applying these findings to future 
treatment and therapeutics in obesity-induced T2D. 
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5.2 FUTURE DIRECTIONS 
As the work in this thesis demonstrates, our lab has developed an in vivo model of 
P-cell specific overexpression of PPARa in the context of obesity-induced T2D to 
examine the effects of P-cell lipotoxicity. It should be noted that this study has allowed 
or group to characterize the physiological consequences of p-cell specific overexpression 
of PPARa in vivo; thus we can now move forward with molecular analyses to uncover 
the mechanisms and specific changes in glucose metabolism in our model of P-cell 
lipotoxicity. In vitro, PPARa overexpression in MIN6 and INS-IE cells has been 
extensively studied by numerous groups (Ravnskjaer et al. 2005; Hellemans et al. 2007; 
Frigerio et al. 2010); therefore the following in vivo studies will be considered. 
There are several avenues that could be explored to further characterize the in 
vivo effects of PPARa overexpression on the pancreatic P-cells in a diet-induced obese 
mouse model. First and foremost immunofluorescent staining of PPARa in the 
pancreatic sections needs to be shown, similar to what is observed in mice overexpressing 
eGFP. This would allow us to correlate the improvements observed in glucose tolerance 
and maintenance of 1st phase insulin secretion with pancreatic PPARa overexpression on 
HFD. To do this, antibodies against PPARa must first be optimized utilizing tissue 
sections that would show positive PPARa staining, such as sections from fasted liver. In 
addition to optimizing antibodies, the immunohistochemical protocols must also be 
optimized for heat-induced epitope retrieval and protein blocking. Once optimized, the 
PPARa antibodies would then be used to stain for PPARa in the p-PPARa-HFD pancreas 
sections; these sections would be compared against no antibody control pancreas sections 
stained only with the secondary antibody to determine levels of positive staining over and 
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above background staining. In addition, dual staining for PPARa + insulin, and PPARa 
+ glucagon would be completed to show that PPARa is being expressed solely in the P-
cells and not the a-cells of the pancreas. If PPARa is being overexpressed in the 
pancreatic p-cells and immunofluorescent staining is not able to detect PPARa above and 
beyond background fluorescence, colormetric staining of PPARa could be an alternative 
solution. Colormetric staining could be advantageous for our sections, as it eliminates the 
autofluorescing from red blood cells that may be present in non-perfused tissue sections. 
Once we are able to show PPARa staining in the pancreatic sections, we could 
then carry out additional studies that would further characterize p-cell specific PPARa 
overexpression in vivo. As work completed in MIN6 cells has been utilized to support 
our in vivo work thus far, utilizing isolated islets from PPARa overexpressing mice 
would be our next option. A second cohort of mice (ideally n=10 mice per group) would 
be infected and subjected to HFD as carried out previously by our group. Having a larger 
cohort of mice would allow our group to collect whole pancreas (n= 1 or 2 per group) 
with the remainder being sacrificed for isolated islets. The whole pancreases would be 
sectioned and stained for PPARa to confirm overexpression. The isolated islets would 
then be utilized for gene expression studies, allowing our group to determine which 
PPARa target genes involved in P-oxidation are upregulated in our model. From our in 
vitro work, we would identify if acyl-CoA oxidase (AOX), carnitine palmitoyl 
transferase-1 (CPT1), long chain acyl-coA dehydrogenase (LCAD), and uncoupling 
protein-2 (UCP2) were upregulated in the pancreatic p-cell. Thus allowing us to correlate 
improvements in glucose tolerance with increased p-oxidation. These studies would 
allow us to further elucidate the mechanisms involved in preventing P-cell lipotoxicity. 
142 
In addition to gene expression studies, lipidomic profiling in isolated islets will be 
performed in collaboration with Matej Oresic from the Technical Research Center of 
Finland, using liquid chromatography-mass spectrometry (LC-MS) lipid profiling 
(Nygren et al. 2011). This study would allow our group to determine the lipid profiles 
and lipid levels in P-PPARa-HFD islets compared to islets from P-eGFP-HFD controls. 
If lipidomic profiling is not a feasible option, our group could also consider isolating 
islets and determining the levels of triglycerides (TGs) utilizing a standard TG 
determination kit (Sigma Aldrich, Oakville ON, Canada). This is a crude measure of 
total TG content, allowing us to determine the levels of lipid accumulation in the p-cells 
of P-PPARa-HFD and P-eGFP-HFD mice; these results could be correlated with levels of 
upregulation of p-oxidative genes or other lipid metabolic pathways observed utilizing 
qRT-PCR. This method would not allow us to determine which lipid species is being 
accumulated by the P-cells, nor will it allow us to distinguish which lipid species is being 
utilized as an activating ligand for PPARa in vivo as no definitive activating ligand has 
been identified outside of the liver (Chakravarthy et al. 2009). An alternative option 
would be to quantify lipid accumulation within pancreatic sections using lipophillic 
histological staining (either Oil Red O staining or BODIPY 493/503 staining); each of 
these methods is cost effective and is considered to be a good method for crude 
quantification of lipids. BODIPY 493/503 is a fluorescent label for lipid droplets (Ohsaki 
et al. 2010). Spangenburg and colleagues (2011) have demonstrated exceptional staining 
of lipid droplets using BODIPY 493/503 in skeletal muscle (Spangenburg et al. 2011). 
Combined immunofluorescent staining for PPARa and BODIPY staining of lipid would 
allow us to visually quantify lipid accumulation within PPARa overexpressing P-cells. 
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If feasible, to further understand the mechanisms involved in preserving p-cell 
function during lipotoxicity, repeating this study with another cohort of mice for taking 
whole pancreas and isolated islets at various time points would be advantageous. This 
type of study would allow us to determine levels of PPARa overexpression over time, as 
well determine the rate at which PPARa overexpressing p-cells are being recycled (Wang 
et al. 2004). Studying the rate of P-cell recycling could potentially explain why 
improving trends and improvements in glucose tolerance were only observed at a single 
time point and significance between P-PPARa-HFD and p-eGFP-HFD mice decreased 
over time. 
In addition to the studies listed above, the use of targeted PPARa delivery using 
dsAAV8 could potentially severe as a preventative therapeutic. One possibility is to 
transfect isolated islets for transplantation with PPARa to protect against lipid 
accumulation and P-cell dysfunction. Isolated islets would be treated with dsAAV8-RIP-
PPARa prior to transplanting in either the kidney capsule or hepatic portal vein of 
streptozotocin (STZ) induced diabetic mice. Mice would be placed on HFD for 20 weeks 
and monitored as previously described. The PPARa-treated transplanted islets (from 
kidney capsule or hepatic portal vien) of STZ-treated mice would be isolated and 
assessed for lipid accumulation. This study would allow us to test the therapeutic 
possibilities of PPARa as a preventative treatment protecting transplanted islets against 
lipotoxic dysfunction. 
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5.3 SIGNIFICANCE 
Characterizing the effect of in vivo pancreatic P-cell specific overexpression of 
PPARa in a model of obesity-induced T2D has provided novel insights on obesity-
induced p-cell lipotoxicity. More importantly, through the duration of my thesis project, 
we have developed the first in vivo model of P-cell specific overexpression of PPARa in 
a model of diet-induced P-cell lipotoxicity using the dsAAV8 as our tool for gene 
delivery. The data collected in this study presents significant information and provides a 
model of protecting P-cell function in diet-induced obesity. My results are summarized 
below: 
1. We have shown using AAV plasmid, in vitro, that PPARa overexpression in 
MIN6 cells occurs at physiological levels when compared to levels observed in 
fasted liver. Additionally, PPARa overexpression upregulates the P-oxidative 
target gene CPT1 in the presence of palmitate. Moreover, MIN6 cells 
overexpressing PPARa maintains glucose-stimulated insulin secretion when 
treated with palmitate. Taken together, these results provide in vitro support that 
our construct can be used to overexpress PPARa in a P-cell cell line. Thus 
allowing us to assess the expected expression levels of PPARa target genes that 
may be involved in P-oxidation in PPARa overexpressing islets in vivo. 
2. In vivo we have shown that dsAAV8 can be delivered through a non-invasive 
intraperitoneal injection to overexpress proteins of interest in the P-cells of the 
pancreas when used with RIP. In addition our group has shown that under the 
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direction of RIP, eGFP does not cross the BBB and is not expressed in the 
hypothalamus of infected mice. Thus dsAAV8 is a successful tool for targeting 
gene delivery to the pancreatic P-cells without expression in peripheral tissues. 
3. Overexpression of eGFP under the direction of RIP does not affect body weight 
or carbohydrate metabolism, therefore can serve as appropriate control vector for 
in vivo studies. 
4. Utilizing p-cell specific overexpression of PPARa during diet-induced obesity 
protects against glucose intolerance. We speculate that these observations may be 
due to decreasing lipid accumulation in the P-cell, preserving P-cell function. Our 
group has demonstrated that overexpressing PPARa in pancreatic P-cells 
maintains 1st phase insulin secretion impaired by obesity without changes in p-cell 
mass. In addition, PPARa overexpression in vivo does not affect body weight 
gain on HFD or insulin sensitivity when compared to obese controls. 
In addition the significance of this study can be addressed as follows: 
1. By manipulating the overexpression of PPARa in the P-cell, which makes up 
approximately 1% of the total weight of the pancreas, we have demonstrated that 
PPARa agonsim can impact whole-animal glucose homeostasis independently of 
systemic effects of liver and muscle lipid metabolism. Moreover, we have shown 
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the physiological phenotype of the first in vivo model of p-cell specific PPARa 
overexpression. 
2. We have demonstrated that targeted overexpression PPARa specifically in 
pancreatic P-cells in vivo preserves p-cell function and protects against glucose 
intolerance in diet-induced obesity. Thus providing an in vivo model to elucidate 
the mechanisms of P-cell lipotoxicity in obesity-induced T2D. 
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Figure SI - (A) The mathematical breakdown on how normal levels of procrastination 
can lead to the development of (B) the Master's thesis. Permission for use of comics 
granted by PHDcomics.com. 
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